[{"ArticleUrl":"http:\/\/www.bing.com\/news\/apiclick.aspx?ref=BDIGeneric&aid=5021FF6D1971DEF2E613F5DAD265192472D38E86&tid=C02406CE3C594E41AFBE24D20DDAED88&url=https%3a%2f%2fwww.engadget.com%2f2017%2f07%2f22%2fasus-rog-zephyrus-review%2f&c=8424686139814829994&mkt=en-us","PublishTime":"35 minutes ago","Source":"Engadget","Thumbnail":{"Height":187,"Url":"http:\/\/www.bing.com\/th?id=ON.7CE097F8A09BAA23895FA85F73095BD4&pid=News&sz=280x187","Width":280},"Title":"ASUS ROG Zephyrus review: Gaming laptops will never be the same again","LtUpDtTm":"\/Date(-62104060800000+0000)\/","PbTmStp":"\/Date(-62104060800000+0000)\/","ProviderLogoUrl":null,"PublishTimeRaw":1.314533988E+17,"Snippet":"The ASUS ROG Zephyrus is an entirely new breed of gaming notebook. It packs in the most powerful laptop graphics hardware on the market, NVIDIA's GTX 1080, in a frame that's almost half the size of similar machines. Mostly, that's due to being one of the ..."},{"ArticleUrl":"http:\/\/www.bing.com\/news\/apiclick.aspx?ref=BDIGeneric&aid=5021FF6D1971DEF2E613F5DAD265192472D38E86&tid=C02406CE3C594E41AFBE24D20DDAED88&url=https%3a%2f%2ftechcrunch.com%2f2017%2f07%2f21%2foptomas-uhd60-projector-delivers-great-affordable-4k-performance%2f&c=12557852218779356687&mkt=en-us","PublishTime":"2 days ago","Source":"TechCrunch","Thumbnail":{"Height":187,"Url":"http:\/\/www.bing.com\/th?id=ON.4D8D84F5EE78E19FBCAC3F9B4A65EAB7&pid=News&sz=280x187","Width":280},"Title":"Optoma’s UHD60 projector delivers great, affordable 4K performance","LtUpDtTm":"\/Date(-62104060800000+0000)\/","PbTmStp":"\/Date(-62104060800000+0000)\/","ProviderLogoUrl":null,"PublishTimeRaw":1.314512238E+17,"Snippet":"It also worked great with content from the PlayStation 4 Pro, as well as my Bell Fibe TV 4K box, and from a high-end Falcon Tiki gaming PC powered by an Nvidia GTX 1080 GPU. Here’s the bottom line: If you’ve been waiting for 4K in a projector ..."},{"ArticleUrl":"http:\/\/www.bing.com\/news\/apiclick.aspx?ref=BDIGeneric&aid=5021FF6D1971DEF2E613F5DAD265192472D38E86&tid=C02406CE3C594E41AFBE24D20DDAED88&url=https%3a%2f%2fseekingalpha.com%2farticle%2f4089195-amd-vega-stillborn&c=9733288013620081380&mkt=en-us","PublishTime":"3 days ago","Source":"Seeking Alpha","Title":"AMD Vega Is Stillborn","LtUpDtTm":"\/Date(-62104060800000+0000)\/","PbTmStp":"\/Date(-62104060800000+0000)\/","ProviderLogoUrl":null,"PublishTimeRaw":1.314505692E+17,"Snippet":"AMD has had nothing to compete with either the Nvidia GTX 1070 or the GTX 1080, based on Nvidia’s Pascal architecture. Only now, nearly 1.5 years later, is AMD getting ready to launch its new Vega architecture, namely the Vega RX for the consumer market."},{"ArticleUrl":"http:\/\/www.bing.com\/news\/apiclick.aspx?ref=BDIGeneric&aid=5021FF6D1971DEF2E613F5DAD265192472D38E86&tid=C02406CE3C594E41AFBE24D20DDAED88&url=https%3a%2f%2fwww.usatoday.com%2fstory%2ftech%2freviewedcom%2f2017%2f07%2f20%2fthe-best-pc-gaming-accessories-of-2017%2f103866656%2f&c=15921190072240881372&mkt=en-us","PublishTime":"3 days ago","Source":"USA Today","Thumbnail":{"Height":187,"Url":"http:\/\/www.bing.com\/th?id=ON.7EDCAFEE667DFD65A88588CE17C3015A&pid=News&sz=280x187","Width":280},"Title":"Here's everything you need to start gaming on your PC","LtUpDtTm":"\/Date(-62104060800000+0000)\/","PbTmStp":"\/Date(-62104060800000+0000)\/","ProviderLogoUrl":null,"PublishTimeRaw":1.31450529E+17,"Snippet":"Running rings around the more expensive MacBook Pro, this Razer features bleeding-edge Nvidia GTX 1060 graphics, a good keyboard, and normal USB ports. Thunderbolt 3 lets you hook up Razer's Core accessory to boost your graphics performance even more."},{"ArticleUrl":"http:\/\/www.bing.com\/news\/apiclick.aspx?ref=BDIGeneric&aid=5021FF6D1971DEF2E613F5DAD265192472D38E86&tid=C02406CE3C594E41AFBE24D20DDAED88&url=https%3a%2f%2fwww.fool.com%2finvesting%2f2017%2f07%2f19%2f2-stocks-with-better-dividends-than-nvidia-corpora.aspx&c=17697908748581697032&mkt=en-us","PublishTime":"4 days ago","Source":"The Motley Fool","Thumbnail":{"Height":187,"Url":"http:\/\/www.bing.com\/th?id=ON.E03981B49C4BF9417EE84C5FF503DF99&pid=News&sz=280x187","Width":280},"Title":"2 Stocks With Better Dividends Than NVIDIA Corporation","LtUpDtTm":"\/Date(-62104060800000+0000)\/","PbTmStp":"\/Date(-62104060800000+0000)\/","ProviderLogoUrl":null,"PublishTimeRaw":1.31449431E+17,"Snippet":"At the same time, the core gaming business is booming, driven by strong sales of the GTX 1000 series graphics cards. Shares of Microsoft have steadily risen over the past five years, gaining nearly 150% in that time. This has pushed the dividend yield ..."},{"ArticleUrl":"http:\/\/www.bing.com\/news\/apiclick.aspx?ref=BDIGeneric&aid=5021FF6D1971DEF2E613F5DAD265192472D38E86&tid=C02406CE3C594E41AFBE24D20DDAED88&url=http%3a%2f%2fwww.thestar.com.my%2ftech%2ftech-news%2f2017%2f07%2f24%2fdominate-your-game%2f&c=13499161673400588395&mkt=en-us","PublishTime":"16 minutes ago","Source":"The Star Online","Thumbnail":{"Height":393,"Url":"http:\/\/www.bing.com\/th?id=ON.E64B27478D90B3F7C1C3B650FD7ED1FE&pid=News&sz=590x393","Width":590},"Title":"Dominate your game with Omen by HP","LtUpDtTm":"\/Date(-62104060800000+0000)\/","PbTmStp":"\/Date(-62104060800000+0000)\/","ProviderLogoUrl":null,"PublishTimeRaw":1.314534102E+17,"Snippet":"Running on Windows 10 Home, the desktop can be configured with two high-performance ­graphics cards – either dual Nvidia GeForce GTX 1080 Ti or dual Radeon 580 – and comes with up to 16GB RAM. For the processor, users get to pick either a 7th ..."},{"ArticleUrl":"http:\/\/www.bing.com\/news\/apiclick.aspx?ref=BDIGeneric&aid=5021FF6D1971DEF2E613F5DAD265192472D38E86&tid=C02406CE3C594E41AFBE24D20DDAED88&url=http%3a%2f%2fwww.pcgamer.com%2fget-an-asus-desktop-with-core-i5-6400-and-geforce-gtx-1060-for-830%2f&c=5784353948373884629&mkt=en-us","PublishTime":"One hour ago","Source":"PC Gamer","Thumbnail":{"Height":393,"Url":"http:\/\/www.bing.com\/th?id=ON.D7FEF80ED8D68575AFACD49A9E07C24E&pid=News&sz=590x393","Width":590},"Title":"Get an Asus desktop with Core i5-6400 and GeForce GTX 1060 for $830","LtUpDtTm":"\/Date(-62104060800000+0000)\/","PbTmStp":"\/Date(-62104060800000+0000)\/","ProviderLogoUrl":null,"PublishTimeRaw":1.314533796E+17,"Snippet":"We will always prefer to roll our own rigs, but if time constraints or other factors have you shopping for pre-built systems, you can get a pretty good deal on relatively powerful Asus desktop at Best Buy. The Asus G11CD is on sale for $830, compared to ..."},{"ArticleUrl":"http:\/\/www.bing.com\/news\/apiclick.aspx?ref=BDIGeneric&aid=5021FF6D1971DEF2E613F5DAD265192472D38E86&tid=C02406CE3C594E41AFBE24D20DDAED88&url=http%3a%2f%2fwww.ovagames.com%2fsniper-elite-4-deluxe-edition-v1-5-0-steampunks.html&c=10963145487840092243&mkt=en-us","PublishTime":"One hour ago","Source":"ovagames.com","Thumbnail":{"Height":100,"Url":"http:\/\/www.bing.com\/th?id=ON.B3FA10EDD07F9314302C25D16C4163E8&pid=News&sz=100x100","Width":100},"Title":"Sniper Elite 4 Deluxe Edition v1.5.0-STEAMPUNKS","LtUpDtTm":"\/Date(-62104060800000+0000)\/","PbTmStp":"\/Date(-62104060800000+0000)\/","ProviderLogoUrl":null,"PublishTimeRaw":1.314533682E+17,"Snippet":"Minimum: • OS: 64-bit Windows 7, 64-bit Windows 8.1 or 64-bit Windows 10 • Processor: Intel CPU Core i3-2100 or AMD equivalent • Memory: 4 GB RAM • Graphics: AMD Radeon HD 7870 (2GB) or NVIDIA GeForce GTX 660 (2GB) Recommended: • OS: 64-bit ..."},{"ArticleUrl":"http:\/\/www.bing.com\/news\/apiclick.aspx?ref=BDIGeneric&aid=5021FF6D1971DEF2E613F5DAD265192472D38E86&tid=C02406CE3C594E41AFBE24D20DDAED88&url=https%3a%2f%2fwww.tonymacx86.com%2fthreads%2fgtx-1050ti-showing-as-nvidia-chip-model-7mb.227860%2f&c=9708202827635480049&mkt=en-us","PublishTime":"2 hours ago","Source":"tonymacx86.com","Title":"Gtx 1050ti showing as nvidia chip model 7mb","LtUpDtTm":"\/Date(-62104060800000+0000)\/","PbTmStp":"\/Date(-62104060800000+0000)\/","ProviderLogoUrl":null,"PublishTimeRaw":1.314533394E+17,"Snippet":"I've tried everything to get my graphics card to work properly! I have the nvidia web drivers installed and fixed my NVRAM issues so the drivers will be the default driver after reset. Adding and removing different boot flags mostly just caused the system ..."},{"ArticleUrl":"http:\/\/www.bing.com\/news\/apiclick.aspx?ref=BDIGeneric&aid=5021FF6D1971DEF2E613F5DAD265192472D38E86&tid=C02406CE3C594E41AFBE24D20DDAED88&url=http%3a%2f%2fspeedsociety.com%2ftour-bill-goldbergs-personal-car-collection-this-guy-knows-his-cars%2f&c=16825982240791154521&mkt=en-us","PublishTime":"7 hours ago","Source":"speedsociety.com","Thumbnail":{"Height":393,"Url":"http:\/\/www.bing.com\/th?id=ON.4DF0741B383C616B8D3BE0F221483499&pid=News&sz=590x393","Width":590},"Title":"Tour Bill Goldberg’s Personal Car Collection, This Guy Knows his Cars!","LtUpDtTm":"\/Date(-62104060800000+0000)\/","PbTmStp":"\/Date(-62104060800000+0000)\/","ProviderLogoUrl":null,"PublishTimeRaw":1.31453148E+17,"Snippet":"From the get-go, we have the opportunity to check out a car that Goldberg says he has had for an incredibly long time in his 1968 Plymouth GTX convertible, his first muscle car that he claims is a perpetual restoration in progress. From there, we get to ..."}]







 GTXI - Stock quote for GTx Inc - MSN Money















msn  back to msn home

money










web search














Sign in








Change language & content:

América Latina (español)
Argentina (español)
Australia (English)
België (Nederlands)
Belgique (français)
Brasil (português)
Canada (English)
Canada (français)
Chile (español)
Colombia (español)
Danmark (Dansk)
Deutschland (Deutsch)
España (español)
France (français)
India (English)
Indonesia (Bahasa Indonesia)
Ireland (English)
Italia (italiano)
Malaysia (English)
México (español)
Nederland (Nederlands)
New Zealand (English)
Norge (norsk, bokmål)
Österreich (Deutsch)
Perú (español)
Philippines (English)
Polska (polski)
Portugal (Português)
Schweiz (Deutsch)
Singapore (English)
South Africa (English)
Suisse (français)
Suomi (suomi)
Sverige (svenska)
Türkiye (Türkçe)
United Arab Emirates (English)
United Kingdom (English)
United States (English)
United States (español)
Venezuela (español)
Việt Nam (Tiếng Việt)
Ελλάδα (ελληνικά)
Россия (Pусский)
ישראל (עברית)‏
الإمارات العربية المتحدة (العربية‏)
المملكة العربية السعودية (العربية‏)
مصر (العربية‏)
ไทย (ไทย)
한국 (한국어)
中华人民共和国 (简体中文)
台灣 (繁體中文)
日本 (日本語)
香港特别行政區 (繁體中文)



Switch to Latino (Español)



 Feedback



Help






























AdChoices














GTx Inc
NASDAQ: GTXI



US Markets Closed










AdChoices








5.60


▼


-0.02
-0.36%



After Hours : 
5.63
+0.03
+0.54%



 July 21, 2017 4:00 PM EDT. Delayed 15 minutes; Source: NASDAQ. Currency In USD                
















Save














            Summary
        



            Financials
        



            Analysis
        



            Options
        



            Ownership
        



            Company
        



            History
        



            Related
        


















































Open
5.64


Previous Close
5.62


Volume (Avg) 
14.86k (220.57k)


Day's Range
5.52-5.66


52Wk Range
2.73-11.19


Market Cap.
89.83M


Dividend Rate ( Yield)
-


Beta
1.67


Shares Outstanding
16.04M


P/E Ratio (EPS)
-









Recent News






 
ASUS ROG Zephyrus review: Gaming laptops will never be the same again

                            
                            Engadget
                        
35 mins ago





 
Optoma’s UHD60 projector delivers great, affordable 4K performance

                            
                            TechCrunch
                        
2 days ago






AMD Vega Is Stillborn

                            
                            Seeking Alpha
                        
3 days ago





 
Here's everything you need to start gaming on your PC

                            
                            USA Today
                        
3 days ago





 
2 Stocks With Better Dividends Than NVIDIA Corporation

                            
                            The Motley Fool
                        
4 days ago





 
Dominate your game with Omen by HP

                            
                            The Star Online
                        
16 mins ago







 
Get an Asus desktop with Core i5-6400 and GeForce GTX 1060 for $830

                            
                            PC Gamer
                        
1 hr ago





 
Sniper Elite 4 Deluxe Edition v1.5.0-STEAMPUNKS

                            
                            ovagames.com
                        
1 hr ago






Gtx 1050ti showing as nvidia chip model 7mb

                            
                            tonymacx86.com
                        
2 hrs ago





 
Tour Bill Goldberg’s Personal Car Collection, This Guy Knows his Cars!

                            
                            speedsociety.com
                        
7 hrs ago





 
Nvidia GTX 770 Graphic's Card Flashed to Mac?

                            
                            tonymacx86.com
                        
10 hrs ago





 
The Pros and Cons of SLI Laptops

                            
                            LAPTOP Magazine
                        
10 hrs ago








Does a monitor need to be plugged into mobo to use onboard graphics?

                            
                            tenforums.com
                        
11 hrs ago






EVGA GeForce GTX 1080 FTW2 GAMING - best OC settings?

                            
                            overclock.net
                        
11 hrs ago





 
Help Me, Laptop! Which 4K Gaming Laptop Is Right for Me?

                            
                            LAPTOP Magazine
                        
12 hrs ago





 
ECCO Cool GTX (Womens) Ultimate Runners Yak/Deco Coral/Dusty Purple ECCO...

                            
                            noholdsbarredgrace.com
                        
15 hrs ago





 
Mazda 323 Review

                            
                            Edmunds
                        
15 hrs ago





 
International Conference on Machine Learning coming to Sydney, featuring NVIDIA AI

                            
                            techau.com.au
                        
20 hrs ago























AdChoices
















AdChoices

















AdChoices




















Markets











DOW

DOW



▼

21,580.07


-31.71
-0.15%













Last updated time
7/21/2017 4:35 PM EDT







Markets





NASDAQ

NASDAQ



▼

6,387.75




-2.25
-0.04%










FTSE 100

FTSE 100



▼

7,452.91




-34.96
-0.47%










NYSE Composite

NYSE Composite



▼

11,924.60




-19.90
-0.17%



















AdChoices
















                Feedback
            







Send Feedback
Provide Feedback
Report a Problem


We appreciate your input!



Select a category:

I'm having problems with Top Destinations
I'm having issues searching
I'm having problems with Featured Apps
I see an error in the content
Other



How we can improve?





Please give an overall site rating:









Submit
Close


Privacy Statement


Help


Help & Support



 











 








Home - GTx




































































Pipeline



We have a broad pipeline of product candidates that target a number of serious diseases. Learn about our pipeline »





News



June 12, 2017GTx Announces Positive Preliminary Results from Ongoing Phase 2 Proof-of-Concept Clinical Trial in Women with Stress Urinary Incontinence MORE »May 15, 2017GTx Provides Corporate Update and Reports First Quarter 2017 Financial Results MORE »












Information Request
Contact
Careers
 

Search








Search:


 




Developing hormone receptor-based medicines, for lif






























				MENU							



About

Overview
Management Team
Board of Directors
Careers
Contact


Pipeline

Overview
Stress Urinary Incontinence
Breast Cancer
Duchenne Muscular Dystrophy
Prostate Cancer


Diseases

Overview
Stress Urinary Incontinence
Breast Cancer
Duchenne Muscular Dystrophy
Prostate Cancer


Science

Overview
Selective Androgen Receptor Modulator (SARM)

The Potential Advantage of SARMs
SARMs in Breast Cancer
SARMs in Muscle Diseases
SARMs in Urology


Selective Androgen Receptor Degrader (SARD)


Investors

Overview
News Releases
Events & Presentations
Financial Reports

SEC Filings


Stock Information

Historic Stock Lookup
Investment Calculator
Analyst Coverage


Corporate Governance

Management
Board of Directors
Committee Composition


Investor FAQs
IRS Form 8937
Contact Us




 





GTXI Stock Price - GTx Inc. Stock Quote (U.S.: Nasdaq) - MarketWatch



























 














































 















Sections

Watchlist




























Signup
 • 
Login

Search







Bulletin











US
Europe
Asia
FX
Rates
Futures


Range


1D
5D
1M
3M
6M
1Y
2Y











Dow

21,580.07


-31.71


-0.15%











S&P 500

2,472.54


-0.91


-0.04%











Nasdaq

6,387.75


-2.25


-0.04%











GlobalDow

2,832.33


-0.87


-0.03%











Gold

1,260.80


-0.20


-0.02%











Oil

45.83


0.06


0.13%

















S&P 500 Movers(%)



CTAS 
9.2




COF 
8.6




ETFC 
5.1




SYF 
4.5






HP
-5.5




ISRG
-4.6




HBAN
-4.4




CHK
-3.1














Latest NewsAll Times Eastern








11:21p

Updated
‘Game of Thrones’: The four biggest takeaways from 'Stormborn’



11:09p

Updated
Why you’re more likely to die in an accident during the summer months



11:08p

Updated
These wealthy parents spend $20,000 for summer camps so their kids can be ‘normal’



11:06p

Updated
5 totally avoidable reasons why millennials can’t have nice things (or save any money)



11:05p

Updated
How Elon Musk and shorter commutes could transform people’s lives



11:04p

Updated
John McCain is a war hero — but think twice before saying he’s ‘battling’ cancer 



11:04p

Updated
The dark side of cruises



5:36p

Updated
At least 9 dead after overheated tractor-trailer found outside Texas Walmart



5:01p

‘Full transparency’ doesn’t mean what Scaramucci apparently thinks it means



5:00p

Stocks brace for volatility in earnings deluge; Fed meeting looms












to be replaced

























































































































    




Home


Investing


Quotes


Stocks


United States


GTXI


Overview



Compare Quotes
Stock Screener
Earnings Calendar
Sectors
Nasdaq

 



GTXI
U.S.: Nasdaq


Join TD Ameritrade

Find a Broker


GTx Inc.

Watchlist 
CreateGTXIAlert



  


Closed

Last Updated: Jul 21, 2017 3:59 p.m. EDT
Delayed quote



$
5.60



-0.02
-0.36%






Previous Close




$5.6200





  









Advanced Charting


1D
5D
1M
3M
6M
YTD
1Y
3Y
All




$
%
Vol


Advanced Charting

  




6.840% vs Avg.




                Volume:               
                
                    14.9K
                


                65 Day Avg. - 217.3K
            





Open: 5.64
Close: 5.60



5.5200
Day Low/High
5.6630





Day Range



2.7300
52 Week Low/High
11.1910


   








Your Watchlist



Customize MarketWatch
Have Watchlists? Log in to see them here or sign up to get started.

Create Account

                    … or Log In

















Symbol
Last
Chg
Chg %

















No Items in Watchlist
There are currently no items in this Watchlist.

Add Ticker to Watchlist




 (Go to Your Watchlist) 




No Saved Watchlists
Create a list of the investments you want to track.

Create Watchlist

                    …or try this starter list






Uh oh
Something went wrong while loading Watchlist.

Go to Watchlist



 

Recently Viewed Tickers



No Recent Tickers
Visit a quote page and your recently viewed tickers will be displayed here.

Search Tickers



















   





Overview


Profile


News


Charts


Financials


Historical Quotes


Analyst Estimates


Options


SEC Filings


Insiders



   




Key Data



Open
$5.64



Day Range
5.5200 - 5.6630



52 Week Range
2.7300 - 11.1910



Market Cap
$89.84M



Shares Outstanding
16.04M



Public Float
4.25M



Beta
1.35



Rev. per Employee
n/a



P/E Ratio
n/a



EPS
$-1.73



Yield
n/a



Dividend
n/a



Ex-Dividend Date
n/a



Short Interest
234.82K
06/30/17


% of Float Shorted
5.52%



Average Volume
217.26K




 


Performance




5 Day


-0.53%







1 Month


16.42%







3 Month


31.46%







YTD


6.06%







1 Year


-3.45%









  

 
 


Recent News



MarketWatch
Other Dow Jones










California doctors charged with insider trading after drug tests halted

May. 19, 2014 at 3:58 p.m. ET
by Russ Britt










Tuesday’s biggest gaining and declining stocks

May. 8, 2012 at 4:55 p.m. ET
by MarketWatch









GTX rallies 12% on FDA update


May. 8, 2012 at 1:17 p.m. ET
by Val Brickates Kennedy









GTx: FDA lifts hold on Capesaris trials


May. 8, 2012 at 7:28 a.m. ET









GTx Inc. up 27% in premarket


May. 7, 2012 at 8:02 a.m. ET
by Steve Gelsi









Gtx responds to FDA halt on Capesaris trial


Apr. 4, 2012 at 7:25 a.m. ET









Tuesday’s biggest gaining & declining stocks


Feb. 21, 2012 at 5:20 p.m. ET
by Kate Gibson









Gtx: FDA halts Capesaris trials on blood-clot risk


Feb. 21, 2012 at 7:47 a.m. ET









Monday’s biggest gaining and declining stocks


Jan. 30, 2012 at 4:49 p.m. ET
by Kate Gibson









GTX soars 35% on analyst upgrade reports


Jan. 30, 2012 at 11:31 a.m. ET
by Val Brickates Kennedy









GTX gains on analyst rating


Jul. 20, 2011 at 12:06 p.m. ET
by Val Brickates Kennedy









Carpenter, Molycorp, Office Depot among gainers


Jun. 20, 2011 at 11:02 a.m. ET
by Tom Bemis









Ten gainers in Wednesday's market


Jun. 8, 2011 at 10:46 a.m. ET
by Craig Tolliver









Wednesday’s biggest gaining and declining stocks


Apr. 13, 2011 at 5:33 p.m. ET
by William Spain









Drug stocks inch higher in afternoon trading


Apr. 13, 2011 at 3:30 p.m. ET
by Val Brickates Kennedy









GTx rockets on analyst upgrade


Apr. 13, 2011 at 10:04 a.m. ET
by Val Brickates Kennedy









GTX falls in drug-stock trading


Mar. 2, 2011 at 2:28 p.m. ET
by Val Brickates Kennedy









Amylin, Illumina gain; drug indexes slip


Oct. 27, 2010 at 11:50 a.m. ET
by Val Brickates Kennedy









Wednesday's biggest gaining and declining stocks


May. 26, 2010 at 2:00 p.m. ET
by MarketWatch









Drug stocks rebound; GTx sinks on failed study


May. 26, 2010 at 10:46 a.m. ET
by Val Brickates Kennedy













Stocks to Watch: Supernus Pharma, Edwards Group, GTx


Aug. 19, 2013 at 10:12 a.m. ET
on The Wall Street Journal










The Best Apps for Keeping Track of Your Kids

Aug. 26, 2012 at 4:00 p.m. ET
on The Wall Street Journal









Weatherford International, GTx: Biggest Price Decliners (WFT, GTXI)


Feb. 21, 2012 at 1:15 p.m. ET
on The Wall Street Journal









Stocks to Watch: Wynn Resorts, Wal-Mart Stores, Macy's and More


Feb. 21, 2012 at 9:17 a.m. ET
on The Wall Street Journal









Excel Maritime Carriers, GTx: Biggest Price Gainers (EXM, GTXI)


Oct. 14, 2011 at 4:52 p.m. ET
on The Wall Street Journal









Inside Track: A Patient/Fan of GTx Buys More


Nov. 9, 2010 at 11:30 p.m. ET
on The Wall Street Journal









Inside Track: A Patient/Fan of GTx Buys More


Nov. 9, 2010 at 6:53 p.m. ET
on The Wall Street Journal









Xerium Technologies, GTx: Biggest Price Decliners (XRM, GTXI)


May. 26, 2010 at 4:51 p.m. ET
on The Wall Street Journal









Xerium Technologies, GTx: Biggest Price Decliners (XRM, GTXI)


May. 26, 2010 at 12:47 p.m. ET
on The Wall Street Journal









Male Birth Control Pill Stops Sperm in Brain


Nov. 14, 2007 at 5:22 p.m. ET
on The Wall Street Journal









Cymer Rises and Beazer Falls 4.2%


May. 1, 2007 at 12:01 a.m. ET
on The Wall Street Journal









GTx, TRW Stumble in Debuts


Feb. 4, 2004 at 12:01 a.m. ET
on The Wall Street Journal














Recent News



Other News
Press Releases






GTx's (GTXI) Enobosarm Positive in Phase II Study; Shares Up
GTx, Inc.'s (GTXI) shares have climbed almost 99% after the company announced positive data from a phase II study, evaluating enobosarm for treating postmenopausal women with stress urinary incontinence.

Jun. 13, 2017 at 10:14 a.m. ET
on Zacks.com





Here’s Why GTx, Inc. (GTXI) Shares Skyrocketed Over 80% Today
It&#8217;s a very rewarding trading day for investors in GTx, Inc. (NASDAQ:GTXI) with shares up ...[...]

Jun. 12, 2017 at 2:44 p.m. ET
on SmarterAnalyst





Premarket Gainers as of 9:05 am
Premarket Gainers as of 9:05 am

Jun. 12, 2017 at 9:18 a.m. ET
on Seeking Alpha





22 Stocks Moving In Monday's Pre-Market Session
22 Stocks Moving In Monday's Pre-Market Session

Jun. 12, 2017 at 7:31 a.m. ET
on benzinga.com





GTx's enobosarm shows treatment effect in mid-stage study in postmenopausal women with stress urinary incontinence; shares up 14% premarket
GTx's enobosarm shows treatment effect in mid-stage study in postmenopausal women with stress urinary incontinence; shares up 14% premarket

Jun. 12, 2017 at 8:03 a.m. ET
on Seeking Alpha





Hottest Manufacturing Stocks Now – NEON TPIV GTXI BMRA


Dec. 12, 2016 at 4:30 p.m. ET
on InvestorPlace.com





Hottest Manufacturing Stocks Now – EBS ACIU VCEL OPHT


Dec. 9, 2016 at 11:00 a.m. ET
on InvestorPlace.com





GTx's enobosarm shows treatment benefit at 24 weeks in mid-stage breast cancer study


Dec. 8, 2016 at 10:43 a.m. ET
on Seeking Alpha





GTX's enobosarm successful in mid-stage breast cancer study; shares up 4%


Nov. 28, 2016 at 9:36 a.m. ET
on Seeking Alpha





GTx (GTXI) Investor Presentation - Slideshow


Nov. 18, 2016 at 2:31 p.m. ET
on Seeking Alpha





Stage 1 milestone met in GTx's mid-stage study of lead product candidate in certain type of breast cancer, trial to advance to Stage 2


Nov. 16, 2016 at 7:43 a.m. ET
on Seeking Alpha





10-Q: GTX INC /DE/


Nov. 7, 2016 at 5:27 p.m. ET
on Edgar Online -  (EDG = 10Q, 10K)





Insider Invests in GTx


Oct. 18, 2016 at 4:27 p.m. ET
on GuruFocus.com





GTx's enobosarm shows positive results in mid-stage breast cancer study; shares up 47%


Sep. 8, 2016 at 1:32 p.m. ET
on Seeking Alpha





10-Q: GTX INC /DE/


Aug. 9, 2016 at 6:59 p.m. ET
on Edgar Online -  (EDG = 10Q, 10K)





GTx (GTXI) Shows Strength: Stock Adds 11.2% in Session


Jun. 21, 2016 at 8:15 a.m. ET
on Zacks.com





GTx's (GTXI) CEO Marc Hanover on Q4 2015 Results - Earnings Call Transcript


Mar. 3, 2016 at 10:21 a.m. ET
on Seeking Alpha





GTx reports Q4 and FY15 results


Mar. 3, 2016 at 9:22 a.m. ET
on Seeking Alpha





GTx (GTXI) Q4 2015 Results - Earnings Call Webcast


Mar. 3, 2016 at 8:55 a.m. ET
on Seeking Alpha





Strength Seen in GTX (GTXI): Stock Adds 7.8% in Session


Dec. 16, 2015 at 8:20 a.m. ET
on Zacks.com









GTx Discusses Key Goals with WSA
GTx Discusses Key Goals with WSA

Jul. 12, 2017 at 1:43 p.m. ET
on Marketwired





Pharma and Biotech Companies Significantly Investing in R&D, Focus on Rising Demand for Advanced Medicines
Pharma and Biotech Companies Significantly Investing in R&D, Focus on Rising Demand for Advanced Medicines

Jun. 13, 2017 at 8:45 a.m. ET
on PR Newswire - PRF





Today's Research Reports on Stocks to Watch: Xbiotech and GTx
Today's Research Reports on Stocks to Watch: Xbiotech and GTx

Jun. 13, 2017 at 8:12 a.m. ET
on ACCESSWIRE





GTx Announces Positive Preliminary Results from Ongoing Phase 2 
      Proof-of-Concept Clinical Trial in Women with Stress Urinary Incontinence
GTx Announces Positive Preliminary Results from Ongoing Phase 2 
      Proof-of-Concept Clinical Trial in Women with Stress Urinary Incontinence

Jun. 12, 2017 at 7:00 a.m. ET
on BusinessWire - BZX





GTx Provides Corporate Update and Reports First Quarter 2017 
      Financial Results
GTx Provides Corporate Update and Reports First Quarter 2017 
      Financial Results

May. 15, 2017 at 7:00 a.m. ET
on BusinessWire - BZX





GTx Announces Acceptance of an Abstract on Preliminary Results from 
      Phase 2 Clinical Trial in Women with Stress Urinary Incontinence at the 
      International Continence Society Annual Meeting
GTx Announces Acceptance of an Abstract on Preliminary Results from 
      Phase 2 Clinical Trial in Women with Stress Urinary Incontinence at the 
      International Continence Society Annual Meeting

May. 11, 2017 at 7:00 a.m. ET
on BusinessWire - BZX





GTx Announces Results from Preclinical Studies of SARMs in Duchenne 
      Muscular Dystrophy Models Published in Human Molecular Genetics
GTx Announces Results from Preclinical Studies of SARMs in Duchenne 
      Muscular Dystrophy Models Published in Human Molecular Genetics

May. 3, 2017 at 7:00 a.m. ET
on BusinessWire - BZX





GTx Provides Corporate Update and Reports Fourth Quarter and Year-End 
      2016 Financial Results


Mar. 15, 2017 at 7:00 a.m. ET
on BusinessWire - BZX





GTx, Inc. to Report Fourth Quarter and Full Year 2016 Financial 
      Results on March 15, 2017


Mar. 7, 2017 at 7:00 a.m. ET
on BusinessWire - BZX





GTx Reports Results from Ongoing Enobosarm Phase 2 Clinical Trial in 
      ER+/AR+ Breast Cancer


Dec. 8, 2016 at 7:00 a.m. ET
on BusinessWire - BZX





GTx, Inc. Announces 1-for-10 Reverse Stock Split


Dec. 5, 2016 at 9:37 a.m. ET
on BusinessWire - BZX





Enobosarm Meets Pre-Specified Primary Efficacy Endpoint in Ongoing 
      Phase 2 Clinical Trial in ER+/AR+ Breast Cancer


Nov. 28, 2016 at 7:00 a.m. ET
on BusinessWire - BZX





GTx Announces Webcast of Corporate Presentation at the 28th 
      Annual Piper Jaffray Healthcare Conference


Nov. 23, 2016 at 7:00 a.m. ET
on BusinessWire - BZX





Blog Coverage GTx Inc. Enobosarm Achieves Stage 1 Milestone


Nov. 17, 2016 at 8:16 a.m. ET
on ACCESSWIRE





GTx Achieves Second Stage 1 Milestone in Phase 2 Clinical Trial of 
      Enobosarm in ER+/AR+ Breast Cancer


Nov. 16, 2016 at 7:00 a.m. ET
on BusinessWire - BZX





GTx Announces Webcast of Corporate Presentation at the Stifel 2016 
      Healthcare Conference


Nov. 11, 2016 at 7:00 a.m. ET
on BusinessWire - BZX





GTx Provides Corporate Update and Reports Third Quarter 2016 
      Financial Results


Nov. 3, 2016 at 7:00 a.m. ET
on BusinessWire - BZX





Significant Investor Maintains Vote Against Proposed Merger of Female Health Company with Aspen Park Pharmaceuticals


Oct. 21, 2016 at 8:00 a.m. ET
on ACCESSWIRE





GTx Announces $14.0 Million Registered Direct Common Stock Offering


Oct. 12, 2016 at 7:00 a.m. ET
on BusinessWire - BZX





GTx Achieves Stage 1 Milestone in Phase 2 Clinical Trial of Enobosarm 
      in ER+/AR+ Breast Cancer


Sep. 8, 2016 at 7:01 a.m. ET
on BusinessWire - BZX











GTx Inc.


            
            GTx, Inc. is a a biopharmaceutical company, which engages in the discovery, development and commercialization of small molecules for the treatment of cancer, including treatments for breast and prostate cancer, and other serious medical conditions. It focuses on developing selective androgen receptor modulators and selective androgen receptor degrader for the treatment of breast cancer, stress urinary incontinence, Duchenne muscular dystrophy, and prostate cancer. The company was founded by Marc Steven Hanover and Mitchell Shuster Steiner on September 24, 1997 and is headquartered in Memphis, TN.

            
            (See Full Profile)


  





Stifel Terminates Coverage On GTx Due To Reallocation Of Resources


Feb. 9, 2015 at 8:35 a.m. ET
on Benzinga.com





 


Competitors




Name
Chg %
Market Cap




Amgen Inc.
0.50%
$132.61B


AVEO Pharmaceuticals Inc.
-1.59%
$273.7M


GlaxoSmithKline PLC ADR
-0.26%
$103.18B


Johnson & Johnson
-0.92%
$364.5B


Eli Lilly & Co.
-0.11%
$93.41B




Competitor Data Provided By


   






   



























Partner Content























Trending Tickers
Powered by 





BZUN

8.33%








GOOGL

0.17%








GBTC

1.53%








MRK

-0.49%








NYT

0.28%
























Advanced Search







Stocks



Columns


Authors


Topics







No results found





























Video Center










Learn more.Storyful, a division of News Corp, which owns MarketWatch, is a leading social media services company headquartered in Dublin, Ireland. Storyful combines world class journalism with industry-leading technology to discover, verify and acquire original content and provide the on-the-ground sources news and media organizations need to tell the stories that matter to their audience.













Stocks Index - Markets Index
























Bulletin






Investor Alert







Tokyo Markets Close in:



Currencies
Europe Markets
London Markets
















Stocks
Rates
Funds
Bonds
Benchmarks
Real Estate Investment Trusts
Futures
American Depository Receipt Stocks
Exchange Traded Notes
Warrants
Indexes
Exchange Traded Funds
Currencies
Crypto Currencies

Browse Stocks
Stocks A-Z


0-9ABCDEFGHIJKLMNOPQRSTUVWXYZOther

Browse by Location

Argentina
Australia
Austria
Bahamas
Bahrain
Belgium
Bermuda
Botswana
Brazil
British Virgin Islands
Canada
Cayman Islands
Chile
China
Colombia
Curacao
Cyprus
Czech Republic
Denmark
Egypt
Estonia
Finland
France
Germany
Gibraltar
Greece
Hong Kong
Hungary
Iceland
India
Indonesia
Ireland
Isle of Man
Israel
Italy
Japan
Jordan
Kazakhstan
Kuwait
Latvia
Lebanon
Liechtenstein
Lithuania
Luxembourg
Malaysia
Malta
Mauritius
Mexico
Monaco
Money Rates
Morocco
Namibia
Netherlands
New Zealand
Norway
Oman
Pakistan
Panama
Peru
Philippines
Poland
Portugal
Qatar
Romania
Russia
Saudi Arabia
Singapore
Slovakia
Slovenia
South Africa
South Korea
Spain
Sri Lanka
Sweden
Switzerland
Taiwan
Thailand
Tunisia
Turkey
Ukraine
United Arab Emirates
United States
Venezuela
Western Samoa












Log In




11:53 PM EDT
July 23, 2017


/marketstate/country/us
New York

	Closed


/marketstate/country/uk
London

	Closed


/marketstate/country/jp
Tokyo

	Open





/marketstate/country/us
 


/marketstate/country/uk
 


/marketstate/country/jp
 











View All



Latest News

/news/latest
11:22p‘Game of Thrones’: The four biggest takeaways from 'Stormborn’
11:09pWhy you’re more likely to die in an accident during the summer months
11:09pThese wealthy parents spend $20,000 for summer camps so their kids can be ‘normal’
11:07p5 totally avoidable reasons why millennials can’t have nice things (or save any money)
11:06pHow Elon Musk and shorter commutes could transform people’s lives
11:05pJohn McCain is a war hero — but think twice before saying he’s ‘battling’ cancer 
11:04pThe dark side of cruises
5:37pAt least 9 dead after overheated tractor-trailer found outside Texas Walmart
5:01p‘Full transparency’ doesn’t mean what Scaramucci apparently thinks it means
5:00pStocks brace for volatility in earnings deluge; Fed meeting looms
4:53pIf you suddenly quit your job like Sean Spicer, here’s what you should do next
4:52pNever (ever) say these things to a co-worker
4:51pMy uncle with dementia needs long-term care — should I refinance his house?
4:49pThis is the deadliest time of your life to put on weight
4:45pWhy house prices in gay neighborhoods are soaring
4:45pNearly 40% of adults don’t have life insurance — these startups are trying to change that
4:44pMarie Kondo says this one thing could be holding you back from falling in love
4:44pThis luxury credit card is only for truly big spenders
4:43pBanks have raised credit-card interest rates — but not savings account rates
12:13aHeavy showers swamp New Orleans street with rainwater
Loading more headlines...




dow

/quotes/zigman/627449/realtime
21,580.07

-31.71
-0.15%





nasdaq

/quotes/zigman/12633936/realtime
6,387.75

-2.25
-0.04%





s&p 500

/quotes/zigman/3870025/realtime
2,472.54

-0.91
-0.04%













Kiosk


1352872800000
1352872800000


The RetireMentors






				Retirement advice from our industry experts
				Our team of financial professionals can help you plan and save 
					for retirement, then 
				live well in it.



/conga/kiosk/retirementors.html
361307




1320411600000
1320616500000


Alerts



/conga/kiosk/alerts.html
310238




1333717800000
1333964100000


Virtual Stock Exchange





Our free stock-market game
				• Trade your virtual portfolio in real time
				• Talk strategies in group discussions
				• Find or create a game that suits you
				• Use our learning center to improve 



/conga/kiosk/games.html
310284




1245657600000
1277280000000


Location Scouts




Housing-market insights from our realty pros
																																																							Plus the latest data from Realtor.com on 21 home markets across the U.S.
• See our complete Real Estate site


/conga/kiosk/real_estate.html
357012




1404799200000
1404799200000


Lazy Portfolios





				Set it and forget it
				Check out the returns on our 8 Lazy Portfolios that are made up 
				of low-cost 
				buy-and-hold index funds.

				• How to create your own Lazy Portfolio


/conga/kiosk/lazy_portfolio.html
313134














MarketWatch.com




Site Index
Topics
Help
Feedback
Newsroom Roster

                    Media Archive
Premium Products
Mobile


Company Info
Code of Conduct
Corrections
Advertising Media Kit
Advertise Locally
Reprints & Licensing
Broker Center

                    Your Ad Choices


Follow MarketWatch


































RSS
Podcasts






WSJ.com
Barron's Online
BigCharts
Virtual Stock Exchange


Financial News London
WSJ.com Small Business
realtor.com
Mansion Global












		Copyright © 2017 MarketWatch, Inc.  All rights reserved.
		By using this site, you agree to the Terms of Service,
        Privacy Policy and Cookie Policy.
	



            Intraday Data provided by SIX Financial Information and subject to terms of use. Historical and current end-of-day data provided by SIX Financial Information. All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.
        






MarketWatch Top Stories
Link to MarketWatch's Slice.

15



















































Stocks Index - Markets Index
























Bulletin






Investor Alert







Tokyo Markets Close in:



Currencies
Europe Markets
London Markets
















Stocks
Rates
Funds
Bonds
Benchmarks
Real Estate Investment Trusts
Futures
American Depository Receipt Stocks
Exchange Traded Notes
Warrants
Indexes
Exchange Traded Funds
Currencies
Crypto Currencies

Browse Stocks
Stocks A-Z


0-9ABCDEFGHIJKLMNOPQRSTUVWXYZOther

Browse by Location

Argentina
Australia
Austria
Bahamas
Bahrain
Belgium
Bermuda
Botswana
Brazil
British Virgin Islands
Canada
Cayman Islands
Chile
China
Colombia
Curacao
Cyprus
Czech Republic
Denmark
Egypt
Estonia
Finland
France
Germany
Gibraltar
Greece
Hong Kong
Hungary
Iceland
India
Indonesia
Ireland
Isle of Man
Israel
Italy
Japan
Jordan
Kazakhstan
Kuwait
Latvia
Lebanon
Liechtenstein
Lithuania
Luxembourg
Malaysia
Malta
Mauritius
Mexico
Monaco
Money Rates
Morocco
Namibia
Netherlands
New Zealand
Norway
Oman
Pakistan
Panama
Peru
Philippines
Poland
Portugal
Qatar
Romania
Russia
Saudi Arabia
Singapore
Slovakia
Slovenia
South Africa
South Korea
Spain
Sri Lanka
Sweden
Switzerland
Taiwan
Thailand
Tunisia
Turkey
Ukraine
United Arab Emirates
United States
Venezuela
Western Samoa












Log In




11:53 PM EDT
July 23, 2017


/marketstate/country/us
New York

	Closed


/marketstate/country/uk
London

	Closed


/marketstate/country/jp
Tokyo

	Open





/marketstate/country/us
 


/marketstate/country/uk
 


/marketstate/country/jp
 











View All



Latest News

/news/latest
11:22p‘Game of Thrones’: The four biggest takeaways from 'Stormborn’
11:09pWhy you’re more likely to die in an accident during the summer months
11:09pThese wealthy parents spend $20,000 for summer camps so their kids can be ‘normal’
11:07p5 totally avoidable reasons why millennials can’t have nice things (or save any money)
11:06pHow Elon Musk and shorter commutes could transform people’s lives
11:05pJohn McCain is a war hero — but think twice before saying he’s ‘battling’ cancer 
11:04pThe dark side of cruises
5:37pAt least 9 dead after overheated tractor-trailer found outside Texas Walmart
5:01p‘Full transparency’ doesn’t mean what Scaramucci apparently thinks it means
5:00pStocks brace for volatility in earnings deluge; Fed meeting looms
4:53pIf you suddenly quit your job like Sean Spicer, here’s what you should do next
4:52pNever (ever) say these things to a co-worker
4:51pMy uncle with dementia needs long-term care — should I refinance his house?
4:49pThis is the deadliest time of your life to put on weight
4:45pWhy house prices in gay neighborhoods are soaring
4:45pNearly 40% of adults don’t have life insurance — these startups are trying to change that
4:44pMarie Kondo says this one thing could be holding you back from falling in love
4:44pThis luxury credit card is only for truly big spenders
4:43pBanks have raised credit-card interest rates — but not savings account rates
12:13aHeavy showers swamp New Orleans street with rainwater
Loading more headlines...




dow

/quotes/zigman/627449/realtime
21,580.07

-31.71
-0.15%





nasdaq

/quotes/zigman/12633936/realtime
6,387.75

-2.25
-0.04%





s&p 500

/quotes/zigman/3870025/realtime
2,472.54

-0.91
-0.04%













Kiosk


1352872800000
1352872800000


The RetireMentors






				Retirement advice from our industry experts
				Our team of financial professionals can help you plan and save 
					for retirement, then 
				live well in it.



/conga/kiosk/retirementors.html
361307




1320411600000
1320616500000


Alerts



/conga/kiosk/alerts.html
310238




1333717800000
1333964100000


Virtual Stock Exchange





Our free stock-market game
				• Trade your virtual portfolio in real time
				• Talk strategies in group discussions
				• Find or create a game that suits you
				• Use our learning center to improve 



/conga/kiosk/games.html
310284




1245657600000
1277280000000


Location Scouts




Housing-market insights from our realty pros
																																																							Plus the latest data from Realtor.com on 21 home markets across the U.S.
• See our complete Real Estate site


/conga/kiosk/real_estate.html
357012




1404799200000
1404799200000


Lazy Portfolios





				Set it and forget it
				Check out the returns on our 8 Lazy Portfolios that are made up 
				of low-cost 
				buy-and-hold index funds.

				• How to create your own Lazy Portfolio


/conga/kiosk/lazy_portfolio.html
313134














MarketWatch.com




Site Index
Topics
Help
Feedback
Newsroom Roster

                    Media Archive
Premium Products
Mobile


Company Info
Code of Conduct
Corrections
Advertising Media Kit
Advertise Locally
Reprints & Licensing
Broker Center

                    Your Ad Choices


Follow MarketWatch


































RSS
Podcasts






WSJ.com
Barron's Online
BigCharts
Virtual Stock Exchange


Financial News London
WSJ.com Small Business
realtor.com
Mansion Global












		Copyright © 2017 MarketWatch, Inc.  All rights reserved.
		By using this site, you agree to the Terms of Service,
        Privacy Policy and Cookie Policy.
	



            Intraday Data provided by SIX Financial Information and subject to terms of use. Historical and current end-of-day data provided by SIX Financial Information. All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.
        






MarketWatch Top Stories
Link to MarketWatch's Slice.

15



















































Stocks/Country/United States Index - Markets Index
























Bulletin






Investor Alert







Tokyo Markets Close in:



Currencies
Europe Markets
London Markets
















Stocks
Rates
Funds
Bonds
Benchmarks
Real Estate Investment Trusts
Futures
American Depository Receipt Stocks
Exchange Traded Notes
Warrants
Indexes
Exchange Traded Funds
Currencies
Crypto Currencies

Location: United States



Name
Exchange
Sector




01 Communique Laboratory Inc. (OCQLF)
OOTC
Software


1347 Property Insurance Holdings Inc. (PIH)
XNAS
Non-Life Insurance


1-800-FLOWERS.COM Inc. Cl A (FLWS)
XNAS
Specialty Retail


1pm Industries Inc. (OPMZ)
OOTC
Food Products


1st Capital Bank (CA) (FISB)
OOTC
Banking


1st Constitution Bancorp (FCCY)
XNAS
Banking


1st NRG Corp. (FNRC)
OOTC
Oil Extraction


1st Source Corp. (SRCE)
XNAS
Banking


2050 Motors Inc. (ETFM)
OOTC
Automobiles


21st Century Fox Inc. Cl A (FOXA)
XNAS
Broadcasting


21st Century Fox Inc. Cl B (FOX)
XNAS
Broadcasting


21Vianet Group Inc. ADR (VNET)
XNAS
Internet/Online


22nd Century Group Inc. (XXII)
XASE
Biotechnology


24/7 Kid Doc Inc. (TVMD)
OOTC
Healthcare Provision


2U Inc. (TWOU)
XNAS
Software


2xLeveraged Long E-TRACS Linked to Wells Fargo Business Development Co. Index 052441 (BDCL)
ARCX
Major International Banks


2xLeveraged Long ETRACS Wells Fargo Business Development (LBDC)
ARCX
Major International Banks


3D Eye Solutions Inc. (TDEY)
OOTC
Motion Picture/Sound Recording


3D Pioneer Systems Inc. (DPSM)
OOTC
Software


3D Systems Corp. (DDD)
XNYS
Computers/Consumer Electronics


3DIcon Corp. (TDCP)
OOTC
Software


3Dshopping.com (THDS)
OOTC
Mixed Retailing


3DX Industries Inc. (DDDX)
OOTC
Computers/Consumer Electronics


3i Group PLC ADR (TGOPY)
OOTC
Finance Companies


3M Co. (MMM)
XNYS
Diversified Holding Companies


3Pea International Inc. (TPNL)
XOTC
Accounting


3Power Energy Group Inc. (PSPW)
OOTC
Renewable Energy Generation


3TL Technologies Corp. (TTMZF)
OOTC
Advertising/Marketing/Public Relations


420 Property Management Inc. (FTPM)
OOTC
Real Estate Agents/Brokers


4Cable TV International Inc. (CATV)
OOTC
Diversified Business Services


4Licensing Corp. (FOURQ)
OOTC
Diversified Business Services


500.com Ltd. ADR (WBAI)
XNYS
Gambling Industries


51job Inc. ADR (JOBS)
XNAS
Employment/Training Services


58.com Inc. ADR (WUBA)
XNYS
Consumer Services


5Barz International Inc. (BARZ)
OOTC
Networking


5N Plus Inc. (FPLSF)
OOTC
Commodity Chemicals


6D Global Technologies Inc. (SIXD)
OOTC
Computer Services


808 Renewable Energy Corp. (RNWR)
OOTC
Multiutilities


88 Energy Ltd. ADR (TNGRY)
OOTC
Oil Extraction


888 Holdings PLC (EIHDF)
OOTC
Gambling Industries


8Point3 Energy Partners LP (CAFD)
XNAS
Renewable Energy Generation


8X8 Inc. (EGHT)
XNAS
Wired Telecommunications Services


A Clean Slate Inc. (DRWN)
OOTC
Diversified Business Services


A&W Revenue Royalties Income Fund (AWRRF)
OOTC
Restaurants


A. H. Belo Corp. Series A (AHC)
XNYS
Publishing


A. Schulman Inc. (SHLM)
XNAS
Commodity Chemicals


A. Schulman Inc. 6% Pfd. (SLMNP)
OOTC
Commodity Chemicals


A.D. Makepeace Co. (MAKE)
OOTC
Farming


A.M. Castle & Co. (CAS)
XNYS
Wholesalers


A.O. Smith Corp. (AOS)
XNYS
Building Materials/Products


A.P. Moeller-Maersk A/S ADR (AMKBY)
OOTC
Water Transport/Shipping


A.P. Moeller-Maersk A/S Series A (AMKAF)
OOTC
Water Transport/Shipping


A.P. Moeller-Maersk A/S Series B (AMKBF)
OOTC
Water Transport/Shipping


A.S. Roma S.p.A. (ASRAF)
OOTC
Recreational Services


A-1 Group Inc. (AWON)
OOTC
Tobacco


A10 Networks Inc. (ATEN)
XNYS
Computer Services


a2 Milk Co. Ltd. (ACOPF)
OOTC
Biotechnology


AAC Holdings Inc. (AAC)
XNYS
Healthcare Provision


AAC Technologies Holdings Inc. (AACAF)
OOTC
Industrial Electronics


AAC Technologies Holdings Inc. ADR (AACAY)
OOTC
Industrial Electronics


AAON Inc. (AAON)
XNAS
Building Materials/Products


AAP Inc. (AAPJ)
OOTC
Food Products


AAR Corp. (AIR)
XNYS
Aerospace Products/Parts


Aaron's Inc. (AAN)
XNYS
Consumer Services


AB Science S.A. (ABSCF)
OOTC
Pharmaceuticals


AB Svensk Exportkredit ELEMENTS linked to MLCX Biofuels Index Total Return (FUE)
ARCX
Finance Companies


AB Svensk Exportkredit ELEMENTS linked to MLCX Grain Index Total Return (GRU)
ARCX
Finance Companies


AB&T Financial Corp. (ABTO)
OOTC
Banking


Abacus Mining & Exploration Corp. (ABCFF)
OOTC
General Mining


Abakan Inc. (ABKI)
OOTC
Industrial Products


Abattis Bioceuticals Corp. (ATTBF)
OOTC
Biotechnology


Abaxis Inc. (ABAX)
XNAS
Medical Equipment/Supplies


ABB Ltd. (ABLZF)
OOTC
Industrial Machinery


ABB Ltd. ADR (ABB)
XNYS
Industrial Machinery


Abbott Laboratories (ABT)
XNYS
Pharmaceuticals


AbbVie Inc. (ABBV)
XNYS
Biotechnology


Abby Inc. (ABBY)
OOTC
Oil Extraction


Abcam PLC (ABCZF)
OOTC
Biotechnology


Abcam PLC ADR (ABCZY)
OOTC
Biotechnology


ABCO Energy Inc. (ABCE)
OOTC
Industrial Machinery


Abcourt Mines Inc. (ABMBF)
OOTC
General Mining


Aben Resources Ltd. (ABNAF)
OOTC
General Mining


Abengoa S.A. B (AGOAF)
OOTC
Construction


Abeona Therapeutics Inc. (ABEO)
XNAS
Biotechnology


Abeona Therapeutics Inc. Wt (ABEOW)
XNAS



Abercrombie & Fitch Co. (ANF)
XNYS
Clothing Retail


Aberdeen Asia-Pacific Income Fund Inc. (FAX)
XASE
Closed-End Funds


Aberdeen Asia-Pacific Income Investment Co. Ltd. (ABAKF)
OOTC
Closed-End Funds


Aberdeen Asset Management PLC (ABDNF)
OOTC
Investment Advisors


Aberdeen Asset Management PLC ADR (ABDNY)
OOTC
Investment Advisors


Aberdeen Australia Equity Fund Inc. (IAF)
XASE
Closed-End Funds


Aberdeen Chile Fund Inc. (CH)
XASE
Closed-End Funds


Aberdeen Emerging Markets Smaller Company Opportunities Fund Inc. (ABE)
XASE
Closed-End Funds


Aberdeen Global Income Fund Inc. (FCO)
XASE
Closed-End Funds


Aberdeen Greater China Fund Inc. (GCH)
XNYS
Closed-End Funds


Aberdeen Indonesia Fund Inc. (IF)
XASE
Closed-End Funds


Aberdeen International Inc. (AABVF)
OOTC
General Mining


Aberdeen Israel Fund Inc. (ISL)
XASE
Closed-End Funds


Aberdeen Japan Equity Fund Inc. (JEQ)
XNYS
Closed-End Funds


Aberdeen Latin America Equity Fund Inc. (LAQ)
XASE
Closed-End Funds


Aberdeen Singapore Fund Inc. (SGF)
XNYS
Closed-End Funds


Abertis Infraestructuras S.A. ADR (ABRTY)
OOTC
Transportation Services


Ability Inc. (ABIL)
XNAS
Precision Products


Ability Inc. Wt (ABIWF)
OOTC



Abiomed Inc. (ABMD)
XNAS
Medical Equipment/Supplies


Abitibi Royalties Inc. (ATBYF)
OOTC
General Mining


Able Energy Inc. (ABLE)
OOTC
Gas Utilities


Ablynx N.V. (ABLYF)
OOTC
Biotechnology


ABM Industries Inc. (ABM)
XNYS
Diversified Business Services


Abraxas Petroleum Corp. (AXAS)
XNAS
Oil Extraction


Absecon Bancorp (ASCN)
OOTC
Banking


Absolute Health & Fitness Inc. (AHFI)
OOTC
Recreational Services


Absolute Software Corp. (ALSWF)
OOTC
Software


ABT Holdings Inc. (ABOT)
OOTC
Precious Metals


Abtech Holdings Inc. (ABHD)
OOTC
Industrial Machinery


ABV Consulting Inc. (ABVN)
OOTC
Advertising/Marketing/Public Relations


AC Immune S.A. (ACIU)
XNAS
Biotechnology


Acacia Communications Inc. (ACIA)
XNAS
Networking


Acacia Diversified Holdings Inc. (ACCA)
OOTC
Specialty Retail


Acacia Mining PLC (ABGLF)
OOTC
Gold


Acacia Research Corp. - Acacia Technologies (ACTG)
XNAS
Diversified Business Services


Acadia Healthcare Co. Inc. (ACHC)
XNAS
Healthcare Provision


ACADIA Pharmaceuticals Inc. (ACAD)
XNAS
Biotechnology


Acadia Realty Trust (AKR)
XNYS



Acadian Timber Corp. (ACAZF)
OOTC
Forestry & Wood Products


Acasti Pharma Inc. (ACST)
XNAS
Pharmaceuticals


Accelera Innovations Inc. (ACNV)
OOTC
Healthcare Provision


Accelerate Diagnostics Inc. (AXDX)
XNAS
Biotechnology


Accelerize Inc. (ACLZ)
XOTC
Life Insurance


Acceleron Pharma Inc. (XLRN)
XNAS
Biotechnology


Accenture PLC Cl A (ACN)
XNYS
Diversified Business Services


Access National Corp. (ANCX)
XNAS
Banking


Access Power Inc. (ACCR)
OOTC
Wired Telecommunications Services


Access Worldwide Communications Inc. (AWWC)
OOTC
Advertising/Marketing/Public Relations


Acciona S.A. (ACXIF)
OOTC
Construction


ACCO Brands Corp. (ACCO)
XNYS
Nondurable Household Products


Accor S.A. (ACRFF)
OOTC
Hotels


Accor S.A. ADR (ACCYY)
OOTC
Hotels


Accordia Golf Co. Ltd. (ACGFF)
OOTC
Recreational Services


Accredited Mortgage Loan REIT Trust 9.75% Perp. Cum. Pfd. Series A (AHHAP)
OOTC
Mortgages


Accretive Health Inc. (ACHI)
OOTC
Healthcare Provision


Accuray Inc. (ARAY)
XNAS
Medical Equipment/Supplies


Accuride Corp. (ACW)
XNYS
Auto & Commercial Vehicle Parts


AcelRx Pharmaceuticals Inc. (ACRX)
XNAS
Pharmaceuticals


Acer Inc. GDR Reg S (ACEYY)
OOTC
Computers/Consumer Electronics


Acerus Pharmaceuticals Corp. (TRLPF)
OOTC
Biotechnology


Aceto Corp. (ACET)
XNAS
Specialty Chemicals


Achaogen Inc. (AKAO)
XNAS
Biotechnology


Achillion Pharmaceuticals Inc. (ACHN)
XNAS
Biotechnology


ACI Worldwide Inc. (ACIW)
XNAS
Software



«1234567891011-2021-3031-4041-5051-6061-7071-8081-9091-94»










Log In




11:53 PM EDT
July 23, 2017


/marketstate/country/us
New York

	Closed


/marketstate/country/uk
London

	Closed


/marketstate/country/jp
Tokyo

	Open





/marketstate/country/us
 


/marketstate/country/uk
 


/marketstate/country/jp
 











View All



Latest News

/news/latest
11:22p‘Game of Thrones’: The four biggest takeaways from 'Stormborn’
11:09pWhy you’re more likely to die in an accident during the summer months
11:09pThese wealthy parents spend $20,000 for summer camps so their kids can be ‘normal’
11:07p5 totally avoidable reasons why millennials can’t have nice things (or save any money)
11:06pHow Elon Musk and shorter commutes could transform people’s lives
11:05pJohn McCain is a war hero — but think twice before saying he’s ‘battling’ cancer 
11:04pThe dark side of cruises
5:37pAt least 9 dead after overheated tractor-trailer found outside Texas Walmart
5:01p‘Full transparency’ doesn’t mean what Scaramucci apparently thinks it means
5:00pStocks brace for volatility in earnings deluge; Fed meeting looms
4:53pIf you suddenly quit your job like Sean Spicer, here’s what you should do next
4:52pNever (ever) say these things to a co-worker
4:51pMy uncle with dementia needs long-term care — should I refinance his house?
4:49pThis is the deadliest time of your life to put on weight
4:45pWhy house prices in gay neighborhoods are soaring
4:45pNearly 40% of adults don’t have life insurance — these startups are trying to change that
4:44pMarie Kondo says this one thing could be holding you back from falling in love
4:44pThis luxury credit card is only for truly big spenders
4:43pBanks have raised credit-card interest rates — but not savings account rates
12:13aHeavy showers swamp New Orleans street with rainwater
Loading more headlines...




dow

/quotes/zigman/627449/realtime
21,580.07

-31.71
-0.15%





nasdaq

/quotes/zigman/12633936/realtime
6,387.75

-2.25
-0.04%





s&p 500

/quotes/zigman/3870025/realtime
2,472.54

-0.91
-0.04%













Kiosk


1352872800000
1352872800000


The RetireMentors






				Retirement advice from our industry experts
				Our team of financial professionals can help you plan and save 
					for retirement, then 
				live well in it.



/conga/kiosk/retirementors.html
361307




1320411600000
1320616500000


Alerts



/conga/kiosk/alerts.html
310238




1333717800000
1333964100000


Virtual Stock Exchange





Our free stock-market game
				• Trade your virtual portfolio in real time
				• Talk strategies in group discussions
				• Find or create a game that suits you
				• Use our learning center to improve 



/conga/kiosk/games.html
310284




1245657600000
1277280000000


Location Scouts




Housing-market insights from our realty pros
																																																							Plus the latest data from Realtor.com on 21 home markets across the U.S.
• See our complete Real Estate site


/conga/kiosk/real_estate.html
357012




1404799200000
1404799200000


Lazy Portfolios





				Set it and forget it
				Check out the returns on our 8 Lazy Portfolios that are made up 
				of low-cost 
				buy-and-hold index funds.

				• How to create your own Lazy Portfolio


/conga/kiosk/lazy_portfolio.html
313134














MarketWatch.com




Site Index
Topics
Help
Feedback
Newsroom Roster

                    Media Archive
Premium Products
Mobile


Company Info
Code of Conduct
Corrections
Advertising Media Kit
Advertise Locally
Reprints & Licensing
Broker Center

                    Your Ad Choices


Follow MarketWatch


































RSS
Podcasts






WSJ.com
Barron's Online
BigCharts
Virtual Stock Exchange


Financial News London
WSJ.com Small Business
realtor.com
Mansion Global












		Copyright © 2017 MarketWatch, Inc.  All rights reserved.
		By using this site, you agree to the Terms of Service,
        Privacy Policy and Cookie Policy.
	



            Intraday Data provided by SIX Financial Information and subject to terms of use. Historical and current end-of-day data provided by SIX Financial Information. All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.
        






MarketWatch Top Stories
Link to MarketWatch's Slice.

15


















































GTXI Stock Price - GTx Inc. Stock Quote (U.S.: Nasdaq) - MarketWatch



























 














































 















Sections

Watchlist




























Signup
 • 
Login

Search







Bulletin











US
Europe
Asia
FX
Rates
Futures


Range


1D
5D
1M
3M
6M
1Y
2Y











Dow

21,580.07


-31.71


-0.15%











S&P 500

2,472.54


-0.91


-0.04%











Nasdaq

6,387.75


-2.25


-0.04%











GlobalDow

2,832.33


-0.87


-0.03%











Gold

1,260.80


-0.20


-0.02%











Oil

45.83


0.06


0.13%

















S&P 500 Movers(%)



CTAS 
9.2




COF 
8.6




ETFC 
5.1




SYF 
4.5






HP
-5.5




ISRG
-4.6




HBAN
-4.4




CHK
-3.1














Latest NewsAll Times Eastern








11:21p

Updated
‘Game of Thrones’: The four biggest takeaways from 'Stormborn’



11:09p

Updated
Why you’re more likely to die in an accident during the summer months



11:08p

Updated
These wealthy parents spend $20,000 for summer camps so their kids can be ‘normal’



11:06p

Updated
5 totally avoidable reasons why millennials can’t have nice things (or save any money)



11:05p

Updated
How Elon Musk and shorter commutes could transform people’s lives



11:04p

Updated
John McCain is a war hero — but think twice before saying he’s ‘battling’ cancer 



11:04p

Updated
The dark side of cruises



5:36p

Updated
At least 9 dead after overheated tractor-trailer found outside Texas Walmart



5:01p

‘Full transparency’ doesn’t mean what Scaramucci apparently thinks it means



5:00p

Stocks brace for volatility in earnings deluge; Fed meeting looms












to be replaced

























































































































    




Home


Investing


Quotes


Stocks


United States


GTXI


Overview



Compare Quotes
Stock Screener
Earnings Calendar
Sectors
Nasdaq

 



GTXI
U.S.: Nasdaq


Join TD Ameritrade

Find a Broker


GTx Inc.

Watchlist 
CreateGTXIAlert



  


Closed

Last Updated: Jul 21, 2017 3:59 p.m. EDT
Delayed quote



$
5.60



-0.02
-0.36%






Previous Close




$5.6200





  









Advanced Charting


1D
5D
1M
3M
6M
YTD
1Y
3Y
All




$
%
Vol


Advanced Charting

  




6.840% vs Avg.




                Volume:               
                
                    14.9K
                


                65 Day Avg. - 217.3K
            





Open: 5.64
Close: 5.60



5.5200
Day Low/High
5.6630





Day Range



2.7300
52 Week Low/High
11.1910


   








Your Watchlist



Customize MarketWatch
Have Watchlists? Log in to see them here or sign up to get started.

Create Account

                    … or Log In

















Symbol
Last
Chg
Chg %

















No Items in Watchlist
There are currently no items in this Watchlist.

Add Ticker to Watchlist




 (Go to Your Watchlist) 




No Saved Watchlists
Create a list of the investments you want to track.

Create Watchlist

                    …or try this starter list






Uh oh
Something went wrong while loading Watchlist.

Go to Watchlist



 

Recently Viewed Tickers



No Recent Tickers
Visit a quote page and your recently viewed tickers will be displayed here.

Search Tickers



















   





Overview


Profile


News


Charts


Financials


Historical Quotes


Analyst Estimates


Options


SEC Filings


Insiders



   




Key Data



Open
$5.64



Day Range
5.5200 - 5.6630



52 Week Range
2.7300 - 11.1910



Market Cap
$89.84M



Shares Outstanding
16.04M



Public Float
4.25M



Beta
1.35



Rev. per Employee
n/a



P/E Ratio
n/a



EPS
$-1.73



Yield
n/a



Dividend
n/a



Ex-Dividend Date
n/a



Short Interest
234.82K
06/30/17


% of Float Shorted
5.52%



Average Volume
217.26K




 


Performance




5 Day


-0.53%







1 Month


16.42%







3 Month


31.46%







YTD


6.06%







1 Year


-3.45%









  

 
 


Recent News



MarketWatch
Other Dow Jones










California doctors charged with insider trading after drug tests halted

May. 19, 2014 at 3:58 p.m. ET
by Russ Britt










Tuesday’s biggest gaining and declining stocks

May. 8, 2012 at 4:55 p.m. ET
by MarketWatch









GTX rallies 12% on FDA update


May. 8, 2012 at 1:17 p.m. ET
by Val Brickates Kennedy









GTx: FDA lifts hold on Capesaris trials


May. 8, 2012 at 7:28 a.m. ET









GTx Inc. up 27% in premarket


May. 7, 2012 at 8:02 a.m. ET
by Steve Gelsi









Gtx responds to FDA halt on Capesaris trial


Apr. 4, 2012 at 7:25 a.m. ET









Tuesday’s biggest gaining & declining stocks


Feb. 21, 2012 at 5:20 p.m. ET
by Kate Gibson









Gtx: FDA halts Capesaris trials on blood-clot risk


Feb. 21, 2012 at 7:47 a.m. ET









Monday’s biggest gaining and declining stocks


Jan. 30, 2012 at 4:49 p.m. ET
by Kate Gibson









GTX soars 35% on analyst upgrade reports


Jan. 30, 2012 at 11:31 a.m. ET
by Val Brickates Kennedy









GTX gains on analyst rating


Jul. 20, 2011 at 12:06 p.m. ET
by Val Brickates Kennedy









Carpenter, Molycorp, Office Depot among gainers


Jun. 20, 2011 at 11:02 a.m. ET
by Tom Bemis









Ten gainers in Wednesday's market


Jun. 8, 2011 at 10:46 a.m. ET
by Craig Tolliver









Wednesday’s biggest gaining and declining stocks


Apr. 13, 2011 at 5:33 p.m. ET
by William Spain









Drug stocks inch higher in afternoon trading


Apr. 13, 2011 at 3:30 p.m. ET
by Val Brickates Kennedy









GTx rockets on analyst upgrade


Apr. 13, 2011 at 10:04 a.m. ET
by Val Brickates Kennedy









GTX falls in drug-stock trading


Mar. 2, 2011 at 2:28 p.m. ET
by Val Brickates Kennedy









Amylin, Illumina gain; drug indexes slip


Oct. 27, 2010 at 11:50 a.m. ET
by Val Brickates Kennedy









Wednesday's biggest gaining and declining stocks


May. 26, 2010 at 2:00 p.m. ET
by MarketWatch









Drug stocks rebound; GTx sinks on failed study


May. 26, 2010 at 10:46 a.m. ET
by Val Brickates Kennedy













Stocks to Watch: Supernus Pharma, Edwards Group, GTx


Aug. 19, 2013 at 10:12 a.m. ET
on The Wall Street Journal










The Best Apps for Keeping Track of Your Kids

Aug. 26, 2012 at 4:00 p.m. ET
on The Wall Street Journal









Weatherford International, GTx: Biggest Price Decliners (WFT, GTXI)


Feb. 21, 2012 at 1:15 p.m. ET
on The Wall Street Journal









Stocks to Watch: Wynn Resorts, Wal-Mart Stores, Macy's and More


Feb. 21, 2012 at 9:17 a.m. ET
on The Wall Street Journal









Excel Maritime Carriers, GTx: Biggest Price Gainers (EXM, GTXI)


Oct. 14, 2011 at 4:52 p.m. ET
on The Wall Street Journal









Inside Track: A Patient/Fan of GTx Buys More


Nov. 9, 2010 at 11:30 p.m. ET
on The Wall Street Journal









Inside Track: A Patient/Fan of GTx Buys More


Nov. 9, 2010 at 6:53 p.m. ET
on The Wall Street Journal









Xerium Technologies, GTx: Biggest Price Decliners (XRM, GTXI)


May. 26, 2010 at 4:51 p.m. ET
on The Wall Street Journal









Xerium Technologies, GTx: Biggest Price Decliners (XRM, GTXI)


May. 26, 2010 at 12:47 p.m. ET
on The Wall Street Journal









Male Birth Control Pill Stops Sperm in Brain


Nov. 14, 2007 at 5:22 p.m. ET
on The Wall Street Journal









Cymer Rises and Beazer Falls 4.2%


May. 1, 2007 at 12:01 a.m. ET
on The Wall Street Journal









GTx, TRW Stumble in Debuts


Feb. 4, 2004 at 12:01 a.m. ET
on The Wall Street Journal














Recent News



Other News
Press Releases






GTx's (GTXI) Enobosarm Positive in Phase II Study; Shares Up
GTx, Inc.'s (GTXI) shares have climbed almost 99% after the company announced positive data from a phase II study, evaluating enobosarm for treating postmenopausal women with stress urinary incontinence.

Jun. 13, 2017 at 10:14 a.m. ET
on Zacks.com





Here’s Why GTx, Inc. (GTXI) Shares Skyrocketed Over 80% Today
It&#8217;s a very rewarding trading day for investors in GTx, Inc. (NASDAQ:GTXI) with shares up ...[...]

Jun. 12, 2017 at 2:44 p.m. ET
on SmarterAnalyst





Premarket Gainers as of 9:05 am
Premarket Gainers as of 9:05 am

Jun. 12, 2017 at 9:18 a.m. ET
on Seeking Alpha





22 Stocks Moving In Monday's Pre-Market Session
22 Stocks Moving In Monday's Pre-Market Session

Jun. 12, 2017 at 7:31 a.m. ET
on benzinga.com





GTx's enobosarm shows treatment effect in mid-stage study in postmenopausal women with stress urinary incontinence; shares up 14% premarket
GTx's enobosarm shows treatment effect in mid-stage study in postmenopausal women with stress urinary incontinence; shares up 14% premarket

Jun. 12, 2017 at 8:03 a.m. ET
on Seeking Alpha





Hottest Manufacturing Stocks Now – NEON TPIV GTXI BMRA


Dec. 12, 2016 at 4:30 p.m. ET
on InvestorPlace.com





Hottest Manufacturing Stocks Now – EBS ACIU VCEL OPHT


Dec. 9, 2016 at 11:00 a.m. ET
on InvestorPlace.com





GTx's enobosarm shows treatment benefit at 24 weeks in mid-stage breast cancer study


Dec. 8, 2016 at 10:43 a.m. ET
on Seeking Alpha





GTX's enobosarm successful in mid-stage breast cancer study; shares up 4%


Nov. 28, 2016 at 9:36 a.m. ET
on Seeking Alpha





GTx (GTXI) Investor Presentation - Slideshow


Nov. 18, 2016 at 2:31 p.m. ET
on Seeking Alpha





Stage 1 milestone met in GTx's mid-stage study of lead product candidate in certain type of breast cancer, trial to advance to Stage 2


Nov. 16, 2016 at 7:43 a.m. ET
on Seeking Alpha





10-Q: GTX INC /DE/


Nov. 7, 2016 at 5:27 p.m. ET
on Edgar Online -  (EDG = 10Q, 10K)





Insider Invests in GTx


Oct. 18, 2016 at 4:27 p.m. ET
on GuruFocus.com





GTx's enobosarm shows positive results in mid-stage breast cancer study; shares up 47%


Sep. 8, 2016 at 1:32 p.m. ET
on Seeking Alpha





10-Q: GTX INC /DE/


Aug. 9, 2016 at 6:59 p.m. ET
on Edgar Online -  (EDG = 10Q, 10K)





GTx (GTXI) Shows Strength: Stock Adds 11.2% in Session


Jun. 21, 2016 at 8:15 a.m. ET
on Zacks.com





GTx's (GTXI) CEO Marc Hanover on Q4 2015 Results - Earnings Call Transcript


Mar. 3, 2016 at 10:21 a.m. ET
on Seeking Alpha





GTx reports Q4 and FY15 results


Mar. 3, 2016 at 9:22 a.m. ET
on Seeking Alpha





GTx (GTXI) Q4 2015 Results - Earnings Call Webcast


Mar. 3, 2016 at 8:55 a.m. ET
on Seeking Alpha





Strength Seen in GTX (GTXI): Stock Adds 7.8% in Session


Dec. 16, 2015 at 8:20 a.m. ET
on Zacks.com









GTx Discusses Key Goals with WSA
GTx Discusses Key Goals with WSA

Jul. 12, 2017 at 1:43 p.m. ET
on Marketwired





Pharma and Biotech Companies Significantly Investing in R&D, Focus on Rising Demand for Advanced Medicines
Pharma and Biotech Companies Significantly Investing in R&D, Focus on Rising Demand for Advanced Medicines

Jun. 13, 2017 at 8:45 a.m. ET
on PR Newswire - PRF





Today's Research Reports on Stocks to Watch: Xbiotech and GTx
Today's Research Reports on Stocks to Watch: Xbiotech and GTx

Jun. 13, 2017 at 8:12 a.m. ET
on ACCESSWIRE





GTx Announces Positive Preliminary Results from Ongoing Phase 2 
      Proof-of-Concept Clinical Trial in Women with Stress Urinary Incontinence
GTx Announces Positive Preliminary Results from Ongoing Phase 2 
      Proof-of-Concept Clinical Trial in Women with Stress Urinary Incontinence

Jun. 12, 2017 at 7:00 a.m. ET
on BusinessWire - BZX





GTx Provides Corporate Update and Reports First Quarter 2017 
      Financial Results
GTx Provides Corporate Update and Reports First Quarter 2017 
      Financial Results

May. 15, 2017 at 7:00 a.m. ET
on BusinessWire - BZX





GTx Announces Acceptance of an Abstract on Preliminary Results from 
      Phase 2 Clinical Trial in Women with Stress Urinary Incontinence at the 
      International Continence Society Annual Meeting
GTx Announces Acceptance of an Abstract on Preliminary Results from 
      Phase 2 Clinical Trial in Women with Stress Urinary Incontinence at the 
      International Continence Society Annual Meeting

May. 11, 2017 at 7:00 a.m. ET
on BusinessWire - BZX





GTx Announces Results from Preclinical Studies of SARMs in Duchenne 
      Muscular Dystrophy Models Published in Human Molecular Genetics
GTx Announces Results from Preclinical Studies of SARMs in Duchenne 
      Muscular Dystrophy Models Published in Human Molecular Genetics

May. 3, 2017 at 7:00 a.m. ET
on BusinessWire - BZX





GTx Provides Corporate Update and Reports Fourth Quarter and Year-End 
      2016 Financial Results


Mar. 15, 2017 at 7:00 a.m. ET
on BusinessWire - BZX





GTx, Inc. to Report Fourth Quarter and Full Year 2016 Financial 
      Results on March 15, 2017


Mar. 7, 2017 at 7:00 a.m. ET
on BusinessWire - BZX





GTx Reports Results from Ongoing Enobosarm Phase 2 Clinical Trial in 
      ER+/AR+ Breast Cancer


Dec. 8, 2016 at 7:00 a.m. ET
on BusinessWire - BZX





GTx, Inc. Announces 1-for-10 Reverse Stock Split


Dec. 5, 2016 at 9:37 a.m. ET
on BusinessWire - BZX





Enobosarm Meets Pre-Specified Primary Efficacy Endpoint in Ongoing 
      Phase 2 Clinical Trial in ER+/AR+ Breast Cancer


Nov. 28, 2016 at 7:00 a.m. ET
on BusinessWire - BZX





GTx Announces Webcast of Corporate Presentation at the 28th 
      Annual Piper Jaffray Healthcare Conference


Nov. 23, 2016 at 7:00 a.m. ET
on BusinessWire - BZX





Blog Coverage GTx Inc. Enobosarm Achieves Stage 1 Milestone


Nov. 17, 2016 at 8:16 a.m. ET
on ACCESSWIRE





GTx Achieves Second Stage 1 Milestone in Phase 2 Clinical Trial of 
      Enobosarm in ER+/AR+ Breast Cancer


Nov. 16, 2016 at 7:00 a.m. ET
on BusinessWire - BZX





GTx Announces Webcast of Corporate Presentation at the Stifel 2016 
      Healthcare Conference


Nov. 11, 2016 at 7:00 a.m. ET
on BusinessWire - BZX





GTx Provides Corporate Update and Reports Third Quarter 2016 
      Financial Results


Nov. 3, 2016 at 7:00 a.m. ET
on BusinessWire - BZX





Significant Investor Maintains Vote Against Proposed Merger of Female Health Company with Aspen Park Pharmaceuticals


Oct. 21, 2016 at 8:00 a.m. ET
on ACCESSWIRE





GTx Announces $14.0 Million Registered Direct Common Stock Offering


Oct. 12, 2016 at 7:00 a.m. ET
on BusinessWire - BZX





GTx Achieves Stage 1 Milestone in Phase 2 Clinical Trial of Enobosarm 
      in ER+/AR+ Breast Cancer


Sep. 8, 2016 at 7:01 a.m. ET
on BusinessWire - BZX











GTx Inc.


            
            GTx, Inc. is a a biopharmaceutical company, which engages in the discovery, development and commercialization of small molecules for the treatment of cancer, including treatments for breast and prostate cancer, and other serious medical conditions. It focuses on developing selective androgen receptor modulators and selective androgen receptor degrader for the treatment of breast cancer, stress urinary incontinence, Duchenne muscular dystrophy, and prostate cancer. The company was founded by Marc Steven Hanover and Mitchell Shuster Steiner on September 24, 1997 and is headquartered in Memphis, TN.

            
            (See Full Profile)


  





Stifel Terminates Coverage On GTx Due To Reallocation Of Resources


Feb. 9, 2015 at 8:35 a.m. ET
on Benzinga.com





 


Competitors




Name
Chg %
Market Cap




Amgen Inc.
0.50%
$132.61B


AVEO Pharmaceuticals Inc.
-1.59%
$273.7M


GlaxoSmithKline PLC ADR
-0.26%
$103.18B


Johnson & Johnson
-0.92%
$364.5B


Eli Lilly & Co.
-0.11%
$93.41B




Competitor Data Provided By


   






   



























Partner Content























Trending Tickers
Powered by 





BZUN

8.33%








GOOGL

0.17%








GBTC

1.53%








MRK

-0.49%








NYT

0.28%
























Advanced Search







Stocks



Columns


Authors


Topics







No results found





























Video Center










Learn more.Storyful, a division of News Corp, which owns MarketWatch, is a leading social media services company headquartered in Dublin, Ireland. Storyful combines world class journalism with industry-leading technology to discover, verify and acquire original content and provide the on-the-ground sources news and media organizations need to tell the stories that matter to their audience.














    GTXI News - GTx Inc. Company News & Press Releases - MarketWatch




































Bulletin






Investor Alert







Tokyo Markets Close in:



Currencies
Europe Markets
London Markets


















Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close































GTx Inc.

                  NASDAQ: GTXI
          



GO



Set Alerts
Find a Broker




Join TD Ameritrade




Market Index


 

Overview
      
Profile
      
News
      
Charts
      
Financials
      
Historical Quotes
      
Analyst Estimates
      
Options
      
SEC Filings
      
Insiders
      


/marketstate/country/us

GTx Inc.



Market closed
 --Quotes are delayed by 20 min
Jul 21, 2017, 3:59 p.m.


GTXI

/quotes/zigman/81798317/composite


$
5.60




Change

-0.02
-0.36%

Volume
Volume 14,860
Quotes are delayed by 20 min








/quotes/zigman/81798317/composite
Previous close

$
			5.62
		


$
				5.60
			
Change

-0.02
-0.36%





Day low
Day high
$5.52
$5.66










52 week low
52 week high

            $2.73
        

            $11.19
        

















/news/latest/company/us/gtxi

      MarketWatch News on GTXI
    





California doctors charged with insider trading after drug tests halted

3:59 p.m. May 19, 2014
 - Russ Britt




 Tuesday’s biggest gaining and declining stocks
4:54 p.m. May 8, 2012
 - MarketWatch




 GTX rallies 12% on FDA update
1:17 p.m. May 8, 2012
 - Val Brickates Kennedy




 GTx: FDA lifts hold on Capesaris trials
7:27 a.m. May 8, 2012
 - MarketWatch.com




 GTx Inc. up 27% in premarket
8:01 a.m. May 7, 2012
 - Steve Gelsi




 Gtx responds to FDA halt on Capesaris trial
7:24 a.m. April 4, 2012
 - MarketWatch.com




 Tuesday’s biggest gaining & declining stocks
6:19 p.m. Feb. 21, 2012
 - Kate Gibson




 Gtx: FDA halts Capesaris trials on blood-clot risk
8:47 a.m. Feb. 21, 2012
 - MarketWatch.com




 Monday’s biggest gaining and declining stocks
5:48 p.m. Jan. 30, 2012
 - Kate Gibson




 GTX soars 35% on analyst upgrade reports
12:31 p.m. Jan. 30, 2012
 - Val Brickates Kennedy




 GTX gains on analyst rating
12:05 p.m. July 20, 2011
 - Val Brickates Kennedy





Carpenter, Molycorp, Office Depot among gainers

11:03 a.m. June 20, 2011
 - Tom Bemis





Ten gainers in Wednesday's market

10:46 a.m. June 8, 2011
 - Craig Tolliver




 Wednesday’s biggest gaining and declining stocks
5:32 p.m. April 13, 2011
 - William Spain




 Drug stocks inch higher in afternoon trading
3:30 p.m. April 13, 2011
 - Val Brickates Kennedy




 GTx rockets on analyst upgrade
10:03 a.m. April 13, 2011
 - Val Brickates Kennedy




 GTX falls in drug-stock trading
3:27 p.m. March 2, 2011
 - Val Brickates Kennedy




 Amylin, Illumina gain; drug indexes slip
11:50 a.m. Oct. 27, 2010
 - Val Brickates Kennedy




 Wednesday's biggest gaining and declining stocks
2:00 p.m. May 26, 2010
 - MarketWatch




 Drug stocks rebound; GTx sinks on failed study
10:46 a.m. May 26, 2010
 - Val Brickates Kennedy


Loading more headlines...









/news/nonmarketwatch/company/us/gtxi

      Other News on GTXI
    





GTx's (GTXI) Enobosarm Positive in Phase II Study; Shares Up

10:14 a.m. June 13, 2017
 - Zacks.com





Premarket Gainers as of 9:05 am

9:18 a.m. June 12, 2017
 - Seeking Alpha





GTx's enobosarm shows treatment effect in mid-stage study in postmenopausal women with stress urinary incontinence; shares up 14% premarket

8:03 a.m. June 12, 2017
 - Seeking Alpha





Hottest Manufacturing Stocks Now – NEON TPIV GTXI BMRA

5:30 p.m. Dec. 12, 2016
 - InvestorPlace.com





Hottest Manufacturing Stocks Now – EBS ACIU VCEL OPHT

12:00 p.m. Dec. 9, 2016
 - InvestorPlace.com





GTx's enobosarm shows treatment benefit at 24 weeks in mid-stage breast cancer study

11:43 a.m. Dec. 8, 2016
 - Seeking Alpha





GTX's enobosarm successful in mid-stage breast cancer study; shares up 4%

10:36 a.m. Nov. 28, 2016
 - Seeking Alpha





GTx (GTXI) Investor Presentation - Slideshow

3:31 p.m. Nov. 18, 2016
 - Seeking Alpha





Stage 1 milestone met in GTx's mid-stage study of lead product candidate in certain type of breast cancer, trial to advance to Stage 2

8:43 a.m. Nov. 16, 2016
 - Seeking Alpha




 10-Q: GTX INC /DE/
6:26 p.m. Nov. 7, 2016
 - Edgar Online -  (EDG = 10Q, 10K)





Insider Invests in GTx

4:27 p.m. Oct. 18, 2016
 - GuruFocus.com





GTx's enobosarm shows positive results in mid-stage breast cancer study; shares up 47%

1:32 p.m. Sept. 8, 2016
 - Seeking Alpha




 10-Q: GTX INC /DE/
6:58 p.m. Aug. 9, 2016
 - Edgar Online -  (EDG = 10Q, 10K)





GTx (GTXI) Shows Strength: Stock Adds 11.2% in Session

8:15 a.m. June 21, 2016
 - Zacks.com





GTx's (GTXI) CEO Marc Hanover on Q4 2015 Results - Earnings Call Transcript

11:21 a.m. March 3, 2016
 - Seeking Alpha





GTx reports Q4 and FY15 results

10:22 a.m. March 3, 2016
 - Seeking Alpha





GTx (GTXI) Q4 2015 Results - Earnings Call Webcast

9:55 a.m. March 3, 2016
 - Seeking Alpha





Strength Seen in GTX (GTXI): Stock Adds 7.8% in Session

9:20 a.m. Dec. 16, 2015
 - Zacks.com





GTx's (GTXI) CEO Marc Hanover on Q3 2015 Results - Earnings Call Transcript

10:16 a.m. Oct. 29, 2015
 - Seeking Alpha





GTx (GTXI) Q3 2015 Results - Earnings Call Webcast

8:55 a.m. Oct. 29, 2015
 - Seeking Alpha


Loading more headlines...







/news/pressrelease/company/us/gtxi

      Press Releases on GTXI
    




 GTx Discusses Key Goals with WSA
1:43 p.m. July 12, 2017
 - Marketwired




 Pharma and Biotech Companies Significantly Investing in R&D, Focus on Rising Demand for Advanced Medicines
8:45 a.m. June 13, 2017
 - PR Newswire - PRF




 Today's Research Reports on Stocks to Watch: Xbiotech and GTx
8:12 a.m. June 13, 2017
 - ACCESSWIRE




 GTx Announces Positive Preliminary Results from Ongoing Phase 2 
      Proof-of-Concept Clinical Trial in Women with Stress Urinary Incontinence
7:00 a.m. June 12, 2017
 - BusinessWire - BZX




 GTx Provides Corporate Update and Reports First Quarter 2017 
      Financial Results
7:00 a.m. May 15, 2017
 - BusinessWire - BZX




 GTx Announces Acceptance of an Abstract on Preliminary Results from 
      Phase 2 Clinical Trial in Women with Stress Urinary Incontinence at the 
      International Continence Society Annual Meeting
7:00 a.m. May 11, 2017
 - BusinessWire - BZX




 GTx Announces Results from Preclinical Studies of SARMs in Duchenne 
      Muscular Dystrophy Models Published in Human Molecular Genetics
7:00 a.m. May 3, 2017
 - BusinessWire - BZX




 GTx Provides Corporate Update and Reports Fourth Quarter and Year-End 
      2016 Financial Results
7:00 a.m. March 15, 2017
 - BusinessWire - BZX




 GTx, Inc. to Report Fourth Quarter and Full Year 2016 Financial 
      Results on March 15, 2017
8:00 a.m. March 7, 2017
 - BusinessWire - BZX




 GTx Reports Results from Ongoing Enobosarm Phase 2 Clinical Trial in 
      ER+/AR+ Breast Cancer
8:00 a.m. Dec. 8, 2016
 - BusinessWire - BZX




 GTx, Inc. Announces 1-for-10 Reverse Stock Split
10:37 a.m. Dec. 5, 2016
 - BusinessWire - BZX




 Enobosarm Meets Pre-Specified Primary Efficacy Endpoint in Ongoing 
      Phase 2 Clinical Trial in ER+/AR+ Breast Cancer
8:00 a.m. Nov. 28, 2016
 - BusinessWire - BZX




 GTx Announces Webcast of Corporate Presentation at the 28th 
      Annual Piper Jaffray Healthcare Conference
8:00 a.m. Nov. 23, 2016
 - BusinessWire - BZX




 Blog Coverage GTx Inc. Enobosarm Achieves Stage 1 Milestone
9:15 a.m. Nov. 17, 2016
 - ACCESSWIRE




 GTx Achieves Second Stage 1 Milestone in Phase 2 Clinical Trial of 
      Enobosarm in ER+/AR+ Breast Cancer
8:00 a.m. Nov. 16, 2016
 - BusinessWire - BZX




 GTx Announces Webcast of Corporate Presentation at the Stifel 2016 
      Healthcare Conference
8:00 a.m. Nov. 11, 2016
 - BusinessWire - BZX




 GTx Provides Corporate Update and Reports Third Quarter 2016 
      Financial Results
7:00 a.m. Nov. 3, 2016
 - BusinessWire - BZX




 Significant Investor Maintains Vote Against Proposed Merger of Female Health Company with Aspen Park Pharmaceuticals
8:00 a.m. Oct. 21, 2016
 - ACCESSWIRE




 GTx Announces $14.0 Million Registered Direct Common Stock Offering
7:00 a.m. Oct. 12, 2016
 - BusinessWire - BZX




 GTx Achieves Stage 1 Milestone in Phase 2 Clinical Trial of Enobosarm 
      in ER+/AR+ Breast Cancer
7:00 a.m. Sept. 8, 2016
 - BusinessWire - BZX


Loading more headlines...


















Trending Tickers


/quotes/zigman/17636479/composite VUZI+15.60%


/quotes/zigman/237947/composite JCP-5.83%


/quotes/zigman/59392505/composite NUGT-2.93%


/quotes/zigman/59386294/composite JNUG-5.94%


/quotes/zigman/65801738/composite TLT+1.11%


X




Powered by














Log In




11:53 PM EDT
July 23, 2017


/marketstate/country/us
New York

	Closed


/marketstate/country/uk
London

	Closed


/marketstate/country/jp
Tokyo

	Open





/marketstate/country/us
 


/marketstate/country/uk
 


/marketstate/country/jp
 











View All



Latest News

/news/latest
11:22p‘Game of Thrones’: The four biggest takeaways from 'Stormborn’
11:09pWhy you’re more likely to die in an accident during the summer months
11:09pThese wealthy parents spend $20,000 for summer camps so their kids can be ‘normal’
11:07p5 totally avoidable reasons why millennials can’t have nice things (or save any money)
11:06pHow Elon Musk and shorter commutes could transform people’s lives
11:05pJohn McCain is a war hero — but think twice before saying he’s ‘battling’ cancer 
11:04pThe dark side of cruises
5:37pAt least 9 dead after overheated tractor-trailer found outside Texas Walmart
5:01p‘Full transparency’ doesn’t mean what Scaramucci apparently thinks it means
5:00pStocks brace for volatility in earnings deluge; Fed meeting looms
4:53pIf you suddenly quit your job like Sean Spicer, here’s what you should do next
4:52pNever (ever) say these things to a co-worker
4:51pMy uncle with dementia needs long-term care — should I refinance his house?
4:49pThis is the deadliest time of your life to put on weight
4:45pWhy house prices in gay neighborhoods are soaring
4:45pNearly 40% of adults don’t have life insurance — these startups are trying to change that
4:44pMarie Kondo says this one thing could be holding you back from falling in love
4:44pThis luxury credit card is only for truly big spenders
4:43pBanks have raised credit-card interest rates — but not savings account rates
12:13aHeavy showers swamp New Orleans street with rainwater
Loading more headlines...




dow

/quotes/zigman/627449/realtime
21,580.07

-31.71
-0.15%





nasdaq

/quotes/zigman/12633936/realtime
6,387.75

-2.25
-0.04%





s&p 500

/quotes/zigman/3870025/realtime
2,472.54

-0.91
-0.04%













Kiosk


1352872800000
1352872800000


The RetireMentors






				Retirement advice from our industry experts
				Our team of financial professionals can help you plan and save 
					for retirement, then 
				live well in it.



/conga/kiosk/retirementors.html
361307




1320411600000
1320616500000


Alerts



/conga/kiosk/alerts.html
310238




1333717800000
1333964100000


Virtual Stock Exchange





Our free stock-market game
				• Trade your virtual portfolio in real time
				• Talk strategies in group discussions
				• Find or create a game that suits you
				• Use our learning center to improve 



/conga/kiosk/games.html
310284




1245657600000
1277280000000


Location Scouts




Housing-market insights from our realty pros
																																																							Plus the latest data from Realtor.com on 21 home markets across the U.S.
• See our complete Real Estate site


/conga/kiosk/real_estate.html
357012




1404799200000
1404799200000


Lazy Portfolios





				Set it and forget it
				Check out the returns on our 8 Lazy Portfolios that are made up 
				of low-cost 
				buy-and-hold index funds.

				• How to create your own Lazy Portfolio


/conga/kiosk/lazy_portfolio.html
313134














MarketWatch.com




Site Index
Topics
Help
Feedback
Newsroom Roster

                    Media Archive
Premium Products
Mobile


Company Info
Code of Conduct
Corrections
Advertising Media Kit
Advertise Locally
Reprints & Licensing
Broker Center

                    Your Ad Choices


Follow MarketWatch


































RSS
Podcasts






WSJ.com
Barron's Online
BigCharts
Virtual Stock Exchange


Financial News London
WSJ.com Small Business
realtor.com
Mansion Global












		Copyright © 2017 MarketWatch, Inc.  All rights reserved.
		By using this site, you agree to the Terms of Service,
        Privacy Policy and Cookie Policy.
	



            Intraday Data provided by SIX Financial Information and subject to terms of use. Historical and current end-of-day data provided by SIX Financial Information. All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.
        






MarketWatch Top Stories
Link to MarketWatch's Slice.

15


























































    GTXI Analyst Estimates - GTx Inc. Analyst Estimates - MarketWatch



































Bulletin






Investor Alert







Tokyo Markets Close in:



Currencies
Europe Markets
London Markets


















Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close































GTx Inc.

                  NASDAQ: GTXI
          



GO



Set Alerts
Find a Broker




Join TD Ameritrade




Market Index


 

Overview
      
Profile
      
News
      
Charts
      
Financials
      
Historical Quotes
      
Analyst Estimates
      
Options
      
SEC Filings
      
Insiders
      


/marketstate/country/us

GTx Inc.



Market closed
 --Quotes are delayed by 20 min
Jul 21, 2017, 3:59 p.m.


GTXI

/quotes/zigman/81798317/composite


$
5.60




Change

-0.02
-0.36%

Volume
Volume 14,860
Quotes are delayed by 20 min








/quotes/zigman/81798317/composite
Previous close

$
			5.62
		


$
				5.60
			
Change

-0.02
-0.36%





Day low
Day high
$5.52
$5.66










52 week low
52 week high

            $2.73
        

            $11.19
        

























Earnings Summaries





Earnings Scheduled For November 10, 2014


6:36 a.m. Nov. 10, 2014

 - Benzinga.com





Earnings Scheduled For March 4, 2014


5:35 a.m. March 4, 2014

 - Benzinga.com









Analyst Recommendations





Stifel Terminates Coverage On GTx Due To Reallocation Of Resources


9:34 a.m. Feb. 9, 2015

 - Benzinga.com












Trending Tickers


/quotes/zigman/17636479/composite VUZI+15.60%


/quotes/zigman/237947/composite JCP-5.83%


/quotes/zigman/59392505/composite NUGT-2.93%


/quotes/zigman/59386294/composite JNUG-5.94%


/quotes/zigman/65801738/composite TLT+1.11%


X




Powered by














Log In




11:53 PM EDT
July 23, 2017


/marketstate/country/us
New York

	Closed


/marketstate/country/uk
London

	Closed


/marketstate/country/jp
Tokyo

	Open





/marketstate/country/us
 


/marketstate/country/uk
 


/marketstate/country/jp
 











View All



Latest News

/news/latest
11:22p‘Game of Thrones’: The four biggest takeaways from 'Stormborn’
11:09pWhy you’re more likely to die in an accident during the summer months
11:09pThese wealthy parents spend $20,000 for summer camps so their kids can be ‘normal’
11:07p5 totally avoidable reasons why millennials can’t have nice things (or save any money)
11:06pHow Elon Musk and shorter commutes could transform people’s lives
11:05pJohn McCain is a war hero — but think twice before saying he’s ‘battling’ cancer 
11:04pThe dark side of cruises
5:37pAt least 9 dead after overheated tractor-trailer found outside Texas Walmart
5:01p‘Full transparency’ doesn’t mean what Scaramucci apparently thinks it means
5:00pStocks brace for volatility in earnings deluge; Fed meeting looms
4:53pIf you suddenly quit your job like Sean Spicer, here’s what you should do next
4:52pNever (ever) say these things to a co-worker
4:51pMy uncle with dementia needs long-term care — should I refinance his house?
4:49pThis is the deadliest time of your life to put on weight
4:45pWhy house prices in gay neighborhoods are soaring
4:45pNearly 40% of adults don’t have life insurance — these startups are trying to change that
4:44pMarie Kondo says this one thing could be holding you back from falling in love
4:44pThis luxury credit card is only for truly big spenders
4:43pBanks have raised credit-card interest rates — but not savings account rates
12:13aHeavy showers swamp New Orleans street with rainwater
Loading more headlines...




dow

/quotes/zigman/627449/realtime
21,580.07

-31.71
-0.15%





nasdaq

/quotes/zigman/12633936/realtime
6,387.75

-2.25
-0.04%





s&p 500

/quotes/zigman/3870025/realtime
2,472.54

-0.91
-0.04%













Kiosk


1352872800000
1352872800000


The RetireMentors






				Retirement advice from our industry experts
				Our team of financial professionals can help you plan and save 
					for retirement, then 
				live well in it.



/conga/kiosk/retirementors.html
361307




1320411600000
1320616500000


Alerts



/conga/kiosk/alerts.html
310238




1333717800000
1333964100000


Virtual Stock Exchange





Our free stock-market game
				• Trade your virtual portfolio in real time
				• Talk strategies in group discussions
				• Find or create a game that suits you
				• Use our learning center to improve 



/conga/kiosk/games.html
310284




1245657600000
1277280000000


Location Scouts




Housing-market insights from our realty pros
																																																							Plus the latest data from Realtor.com on 21 home markets across the U.S.
• See our complete Real Estate site


/conga/kiosk/real_estate.html
357012




1404799200000
1404799200000


Lazy Portfolios





				Set it and forget it
				Check out the returns on our 8 Lazy Portfolios that are made up 
				of low-cost 
				buy-and-hold index funds.

				• How to create your own Lazy Portfolio


/conga/kiosk/lazy_portfolio.html
313134














MarketWatch.com




Site Index
Topics
Help
Feedback
Newsroom Roster

                    Media Archive
Premium Products
Mobile


Company Info
Code of Conduct
Corrections
Advertising Media Kit
Advertise Locally
Reprints & Licensing
Broker Center

                    Your Ad Choices


Follow MarketWatch


































RSS
Podcasts






WSJ.com
Barron's Online
BigCharts
Virtual Stock Exchange


Financial News London
WSJ.com Small Business
realtor.com
Mansion Global












		Copyright © 2017 MarketWatch, Inc.  All rights reserved.
		By using this site, you agree to the Terms of Service,
        Privacy Policy and Cookie Policy.
	



            Intraday Data provided by SIX Financial Information and subject to terms of use. Historical and current end-of-day data provided by SIX Financial Information. All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.
        






MarketWatch Top Stories
Link to MarketWatch's Slice.

15

























































GTXI Annual Income Statement - GTx Inc. Annual Financials



































Bulletin






Investor Alert







Tokyo Markets Close in:



Currencies
Europe Markets
London Markets


















Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close































GTx Inc.

                  NASDAQ: GTXI
          



GO



Set Alerts
Find a Broker




Join TD Ameritrade




Market Index


 

Overview
      
Profile
      
News
      
Charts
      
Financials
      
Historical Quotes
      
Analyst Estimates
      
Options
      
SEC Filings
      
Insiders
      


/marketstate/country/us

GTx Inc.



Market closed
 --Quotes are delayed by 20 min
Jul 21, 2017, 3:59 p.m.


GTXI

/quotes/zigman/81798317/composite


$
5.60




Change

-0.02
-0.36%

Volume
Volume 14,860
Quotes are delayed by 20 min








/quotes/zigman/81798317/composite
Previous close

$
			5.62
		


$
				5.60
			
Change

-0.02
-0.36%





Day low
Day high
$5.52
$5.66










52 week low
52 week high

            $2.73
        

            $11.19
        


















Income Statement


Balance Sheet


Cash Flow Statement


Annual Financials
Quarter Financials




Annual Financials for GTx Inc.


View Ratios




Fiscal year is January-December. All values USD millions.
20122013201420152016
5-year trend





 Sales/Revenue
            
-----


Sales Growth
-----


 Cost of Goods Sold (COGS) incl. D&A
750,000384,000102,00043,00028,000


COGS excluding D&A
-----


Depreciation & Amortization Expense
750,000384,000102,00043,00028,000


Depreciation
730,000369,00088,00027,00014,000


Amortization of Intangibles
20,00015,00014,00016,00014,000


COGS Growth
--48.80%-73.44%-57.84%-34.88%


 Gross Income
(750,000)(384,000)(102,000)(43,000)(28,000)


Gross Income Growth
-48.80%73.44%57.84%34.88%


Gross Profit Margin
-----NA









20122013201420152016
5-year trend




 SG&A Expense
48.98M41.91M30.25M21.8M25.91M


Research & Development
38.6M31.19M20.87M13.61M17.23M


Other SG&A
10.39M10.72M9.38M8.19M8.68M


SGA Growth
--14.44%-27.83%-27.93%18.84%


Other Operating Expense
-----


Unusual Expense
-1.31M8.8M(3.08M)(8.16M)


EBIT after Unusual Expense
-(43.6M)(39.15M)(18.76M)(17.77M)


Non Operating Income/Expense
(19,000)1.49M(259,000)57,00046,000


Non-Operating Interest Income
-----


Equity in Affiliates (Pretax)
-----


 Interest Expense
-----


Interest Expense Growth
-----


Gross Interest Expense
-----


Interest Capitalized
-----


 Pretax Income
(49.75M)(42.11M)(39.41M)(18.7M)(17.72M)


Pretax Income Growth
-15.36%6.41%52.54%5.23%


Pretax Margin
-----NA


Income Tax
(8.82M)----


Income Tax - Current Domestic
-----


Income Tax - Current Foreign
-----


Income Tax - Deferred Domestic
-----


Income Tax - Deferred Foreign
-----


Income Tax Credits
-----


Equity in Affiliates
-----


Other After Tax Income (Expense)
-----


Consolidated Net Income
(40.93M)(42.11M)(39.41M)(18.7M)(17.72M)


Minority Interest Expense
-----


 Net Income
(40.93M)(42.11M)(39.41M)(18.7M)(17.72M)


Net Income Growth
--2.89%6.41%52.54%5.23%


Net Margin Growth
-----NA


Extraordinaries & Discontinued Operations
13.86M----


Extra Items & Gain/Loss Sale Of Assets
-----


Cumulative Effect - Accounting Chg
-----


Discontinued Operations
13.86M----


Net Income After Extraordinaries
(27.08M)(42.11M)(39.41M)(18.7M)(17.72M)


Preferred Dividends
-----


Net Income Available to Common
(27.08M)(42.11M)(39.41M)(18.7M)(17.72M)


 EPS (Basic)
(4.30)(6.70)(4.80)(1.30)(1.22)


EPS (Basic) Growth
--55.81%28.36%72.92%6.15%


Basic Shares Outstanding
6.28M6.31M8.18M14.04M14.56M


 EPS (Diluted)
(4.30)(6.70)(4.80)(1.50)(1.22)


EPS (Diluted) Growth
--55.81%28.36%68.75%18.67%


Diluted Shares Outstanding
6.28M6.31M8.18M14.78M14.56M


 EBITDA
(48.98M)(41.91M)(30.25M)(21.8M)(25.91M)


EBITDA Growth
-14.44%27.83%27.93%-18.84%


EBITDA Margin
-----NA




            Copyright 2017 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
        














Log In




11:53 PM EDT
July 23, 2017


/marketstate/country/us
New York

	Closed


/marketstate/country/uk
London

	Closed


/marketstate/country/jp
Tokyo

	Open





/marketstate/country/us
 


/marketstate/country/uk
 


/marketstate/country/jp
 











View All



Latest News

/news/latest
11:22p‘Game of Thrones’: The four biggest takeaways from 'Stormborn’
11:09pWhy you’re more likely to die in an accident during the summer months
11:09pThese wealthy parents spend $20,000 for summer camps so their kids can be ‘normal’
11:07p5 totally avoidable reasons why millennials can’t have nice things (or save any money)
11:06pHow Elon Musk and shorter commutes could transform people’s lives
11:05pJohn McCain is a war hero — but think twice before saying he’s ‘battling’ cancer 
11:04pThe dark side of cruises
5:37pAt least 9 dead after overheated tractor-trailer found outside Texas Walmart
5:01p‘Full transparency’ doesn’t mean what Scaramucci apparently thinks it means
5:00pStocks brace for volatility in earnings deluge; Fed meeting looms
4:53pIf you suddenly quit your job like Sean Spicer, here’s what you should do next
4:52pNever (ever) say these things to a co-worker
4:51pMy uncle with dementia needs long-term care — should I refinance his house?
4:49pThis is the deadliest time of your life to put on weight
4:45pWhy house prices in gay neighborhoods are soaring
4:45pNearly 40% of adults don’t have life insurance — these startups are trying to change that
4:44pMarie Kondo says this one thing could be holding you back from falling in love
4:44pThis luxury credit card is only for truly big spenders
4:43pBanks have raised credit-card interest rates — but not savings account rates
12:13aHeavy showers swamp New Orleans street with rainwater
Loading more headlines...




dow

/quotes/zigman/627449/realtime
21,580.07

-31.71
-0.15%





nasdaq

/quotes/zigman/12633936/realtime
6,387.75

-2.25
-0.04%





s&p 500

/quotes/zigman/3870025/realtime
2,472.54

-0.91
-0.04%













Kiosk


1352872800000
1352872800000


The RetireMentors






				Retirement advice from our industry experts
				Our team of financial professionals can help you plan and save 
					for retirement, then 
				live well in it.



/conga/kiosk/retirementors.html
361307




1320411600000
1320616500000


Alerts



/conga/kiosk/alerts.html
310238




1333717800000
1333964100000


Virtual Stock Exchange





Our free stock-market game
				• Trade your virtual portfolio in real time
				• Talk strategies in group discussions
				• Find or create a game that suits you
				• Use our learning center to improve 



/conga/kiosk/games.html
310284




1245657600000
1277280000000


Location Scouts




Housing-market insights from our realty pros
																																																							Plus the latest data from Realtor.com on 21 home markets across the U.S.
• See our complete Real Estate site


/conga/kiosk/real_estate.html
357012




1404799200000
1404799200000


Lazy Portfolios





				Set it and forget it
				Check out the returns on our 8 Lazy Portfolios that are made up 
				of low-cost 
				buy-and-hold index funds.

				• How to create your own Lazy Portfolio


/conga/kiosk/lazy_portfolio.html
313134














MarketWatch.com




Site Index
Topics
Help
Feedback
Newsroom Roster

                    Media Archive
Premium Products
Mobile


Company Info
Code of Conduct
Corrections
Advertising Media Kit
Advertise Locally
Reprints & Licensing
Broker Center

                    Your Ad Choices


Follow MarketWatch


































RSS
Podcasts






WSJ.com
Barron's Online
BigCharts
Virtual Stock Exchange


Financial News London
WSJ.com Small Business
realtor.com
Mansion Global












		Copyright © 2017 MarketWatch, Inc.  All rights reserved.
		By using this site, you agree to the Terms of Service,
        Privacy Policy and Cookie Policy.
	



            Intraday Data provided by SIX Financial Information and subject to terms of use. Historical and current end-of-day data provided by SIX Financial Information. All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.
        






MarketWatch Top Stories
Link to MarketWatch's Slice.

15



























































    GTXI Insider Trading - GTx Inc. Transactions - MarketWatch



































Bulletin






Investor Alert







Tokyo Markets Close in:



Currencies
Europe Markets
London Markets


















Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close































GTx Inc.

                  NASDAQ: GTXI
          



GO



Set Alerts
Find a Broker




Join TD Ameritrade




Market Index


 

Overview
      
Profile
      
News
      
Charts
      
Financials
      
Historical Quotes
      
Analyst Estimates
      
Options
      
SEC Filings
      
Insiders
      


/marketstate/country/us

GTx Inc.



Market closed
 --Quotes are delayed by 20 min
Jul 21, 2017, 3:59 p.m.


GTXI

/quotes/zigman/81798317/composite


$
5.60




Change

-0.02
-0.36%

Volume
Volume 14,860
Quotes are delayed by 20 min








/quotes/zigman/81798317/composite
Previous close

$
			5.62
		


$
				5.60
			
Change

-0.02
-0.36%





Day low
Day high
$5.52
$5.66










52 week low
52 week high

            $2.73
        

            $11.19
        




















Insider Actions for GTx Inc.



 – Purchase

 – Sale
1
 – Number of Transactions











{"OrganizationDocuments":[{"Documents":[{"document":[{"reportDateGroup":[{"reportDate":"2011-06-09","tradeTypeGroup":[{"numTransactions":"5","tradeType":"A"}]},{"reportDate":"2011-05-17","tradeTypeGroup":[{"numTransactions":"3","tradeType":"D"},{"numTransactions":"1","tradeType":"A"}]},{"reportDate":"2011-05-16","tradeTypeGroup":[{"numTransactions":"2","tradeType":"D"},{"numTransactions":"8","tradeType":"A"}]},{"reportDate":"2011-05-13","tradeTypeGroup":[{"numTransactions":"1","tradeType":"D"}]},{"reportDate":"2011-05-12","tradeTypeGroup":[{"numTransactions":"1","tradeType":"D"}]},{"reportDate":"2011-05-11","tradeTypeGroup":[{"numTransactions":"1","tradeType":"D"}]},{"reportDate":"2011-05-02","tradeTypeGroup":[{"numTransactions":"1","tradeType":"D"}]},{"reportDate":"2011-03-10","tradeTypeGroup":[{"numTransactions":"5","tradeType":"A"}]},{"reportDate":"2011-02-17","tradeTypeGroup":[{"numTransactions":"4","tradeType":"D"},{"numTransactions":"2","tradeType":"A"}]},{"reportDate":"2011-02-15","tradeTypeGroup":[{"numTransactions":"8","tradeType":"A"},{"numTransactions":"1","tradeType":"D"}]}]}]}]}]}

Date
Name
Shares
Transaction
Value





07/03/2017

Kenneth S. Robinson 
Director

2,543


 
Award at $5.26 per share.


13,376


07/03/2017

Garry Arthur Neil 
Director

2,376


 
Award at $5.26 per share.


12,497


04/03/2017

Kenneth S. Robinson 
Director

2,730


 
Award at $4.9 per share.


13,377


04/03/2017

Garry Arthur Neil 
Director

2,551


 
Award at $4.9 per share.


12,499


01/03/2017

Kenneth S. Robinson 
Director

2,567


 
Award at $5.21 per share.


13,374


01/03/2017

Garry Arthur Neil 
Director

2,399


 
Award at $5.21 per share.


12,498


10/28/2016

Diane C. Young 
VP, Chief Medical Officer

500


 
Disposition at $7.7 per share.


3,850


10/14/2016

Marc Steven Hanover 
Chief Executive Officer; Director

123,456


 
Award at $0.81 per share.


99,999


10/14/2016

Robert James Wills 
Executive Chairman; Director

123,456


 
Award at $0.81 per share.


99,999


10/14/2016

The Pyramid Peak Foundation                            


7,716,049


 
Acquisition at $0.81 per share.


6,249,999


10/03/2016

Kenneth S. Robinson 
Director

17,599


 
Award at $0 per share.


0


10/03/2016

Garry Arthur Neil 
Director

16,447


 
Award at $0 per share.


0


09/01/2016

Garry Arthur Neil 
Director

7,310


 
Award at $0 per share.


0


07/01/2016

Kenneth S. Robinson 
Director

24,318


 
Award at $0 per share.


0


06/16/2016

Robert James Wills 
Executive Chairman; Director

100,000


 
Acquisition at $0.65 per share.


65,000


04/01/2016

Kenneth S. Robinson 
Director

23,884


 
Award at $0 per share.


0





        Copyright 2017 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
    










Transaction Summary
Total insider purchases and sales reported to the SEC



Timeframe
Transactions
Shares




Last 3 months



                    2
                
 Purchases



                    0
                
 Sales



4,919
0



Last 6 months



                    4
                
 Purchases



                    0
                
 Sales



10,200
0



Last 12 months



                    12
                
 Purchases



                    1
                
 Sales



8,019,483
500







            Officers and Executives
        





Dr. Robert James Wills 
Executive Chairman




Mr. Marc Steven Hanover 
Chief Executive Officer & Director




Mr. Jason T. Shackelford 
Principal Financial & Accounting Officer




Dr. Diane C. Young 
Chief Medical Officer & Vice President




Dr. Mary Ann  Johnston 
VP-Medical Affairs & Clinical Operations




Mr. Jeffrey G. Hesselberg 
Vice President-Regulatory Affairs




Mr. Henry Patton Doggrell 
Secretary, Chief Legal Officer & Vice President




Mr. Joseph R. Hyde 
Lead Independent Director




Dr. Garry Arthur Neil 
Independent Director




Dr. Michael G. Carter 
Independent Director




Dr. Kenneth S. Robinson 
Independent Director




Mr. J. Kenneth Glass 
Independent Director









Trending Tickers


/quotes/zigman/17636479/composite VUZI+15.60%


/quotes/zigman/237947/composite JCP-5.83%


/quotes/zigman/59392505/composite NUGT-2.93%


/quotes/zigman/59386294/composite JNUG-5.94%


/quotes/zigman/65801738/composite TLT+1.11%


X




Powered by














Log In




11:53 PM EDT
July 23, 2017


/marketstate/country/us
New York

	Closed


/marketstate/country/uk
London

	Closed


/marketstate/country/jp
Tokyo

	Open





/marketstate/country/us
 


/marketstate/country/uk
 


/marketstate/country/jp
 











View All



Latest News

/news/latest
11:22p‘Game of Thrones’: The four biggest takeaways from 'Stormborn’
11:09pWhy you’re more likely to die in an accident during the summer months
11:09pThese wealthy parents spend $20,000 for summer camps so their kids can be ‘normal’
11:07p5 totally avoidable reasons why millennials can’t have nice things (or save any money)
11:06pHow Elon Musk and shorter commutes could transform people’s lives
11:05pJohn McCain is a war hero — but think twice before saying he’s ‘battling’ cancer 
11:04pThe dark side of cruises
5:37pAt least 9 dead after overheated tractor-trailer found outside Texas Walmart
5:01p‘Full transparency’ doesn’t mean what Scaramucci apparently thinks it means
5:00pStocks brace for volatility in earnings deluge; Fed meeting looms
4:53pIf you suddenly quit your job like Sean Spicer, here’s what you should do next
4:52pNever (ever) say these things to a co-worker
4:51pMy uncle with dementia needs long-term care — should I refinance his house?
4:49pThis is the deadliest time of your life to put on weight
4:45pWhy house prices in gay neighborhoods are soaring
4:45pNearly 40% of adults don’t have life insurance — these startups are trying to change that
4:44pMarie Kondo says this one thing could be holding you back from falling in love
4:44pThis luxury credit card is only for truly big spenders
4:43pBanks have raised credit-card interest rates — but not savings account rates
12:13aHeavy showers swamp New Orleans street with rainwater
Loading more headlines...




dow

/quotes/zigman/627449/realtime
21,580.07

-31.71
-0.15%





nasdaq

/quotes/zigman/12633936/realtime
6,387.75

-2.25
-0.04%





s&p 500

/quotes/zigman/3870025/realtime
2,472.54

-0.91
-0.04%













Kiosk


1352872800000
1352872800000


The RetireMentors






				Retirement advice from our industry experts
				Our team of financial professionals can help you plan and save 
					for retirement, then 
				live well in it.



/conga/kiosk/retirementors.html
361307




1320411600000
1320616500000


Alerts



/conga/kiosk/alerts.html
310238




1333717800000
1333964100000


Virtual Stock Exchange





Our free stock-market game
				• Trade your virtual portfolio in real time
				• Talk strategies in group discussions
				• Find or create a game that suits you
				• Use our learning center to improve 



/conga/kiosk/games.html
310284




1245657600000
1277280000000


Location Scouts




Housing-market insights from our realty pros
																																																							Plus the latest data from Realtor.com on 21 home markets across the U.S.
• See our complete Real Estate site


/conga/kiosk/real_estate.html
357012




1404799200000
1404799200000


Lazy Portfolios





				Set it and forget it
				Check out the returns on our 8 Lazy Portfolios that are made up 
				of low-cost 
				buy-and-hold index funds.

				• How to create your own Lazy Portfolio


/conga/kiosk/lazy_portfolio.html
313134














MarketWatch.com




Site Index
Topics
Help
Feedback
Newsroom Roster

                    Media Archive
Premium Products
Mobile


Company Info
Code of Conduct
Corrections
Advertising Media Kit
Advertise Locally
Reprints & Licensing
Broker Center

                    Your Ad Choices


Follow MarketWatch


































RSS
Podcasts






WSJ.com
Barron's Online
BigCharts
Virtual Stock Exchange


Financial News London
WSJ.com Small Business
realtor.com
Mansion Global












		Copyright © 2017 MarketWatch, Inc.  All rights reserved.
		By using this site, you agree to the Terms of Service,
        Privacy Policy and Cookie Policy.
	



            Intraday Data provided by SIX Financial Information and subject to terms of use. Historical and current end-of-day data provided by SIX Financial Information. All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.
        






MarketWatch Top Stories
Link to MarketWatch's Slice.

15


























































    GTXI Historical Stock Quotes - GTx Inc. Historical Stock Quotes - MarketWatch




































Bulletin






Investor Alert







Tokyo Markets Close in:



Currencies
Europe Markets
London Markets


















Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close































GTx Inc.

                  NASDAQ: GTXI
          



GO



Set Alerts
Find a Broker




Join TD Ameritrade




Market Index


 

Overview
      
Profile
      
News
      
Charts
      
Financials
      
Historical Quotes
      
Analyst Estimates
      
Options
      
SEC Filings
      
Insiders
      


/marketstate/country/us

GTx Inc.



Market closed
 --Quotes are delayed by 20 min
Jul 21, 2017, 3:59 p.m.


GTXI

/quotes/zigman/81798317/composite


$
5.60




Change

-0.02
-0.36%

Volume
Volume 14,860
Quotes are delayed by 20 min








/quotes/zigman/81798317/composite
Previous close

$
			5.62
		


$
				5.60
			
Change

-0.02
-0.36%





Day low
Day high
$5.52
$5.66










52 week low
52 week high

            $2.73
        

            $11.19
        















Enter Date:



Historical quote for: GTXI



Friday, July 22, 2016


Closing price:



Open:



High:



Low:



Volume:


$0.58
Unadjusted price:


0.1000
Adjustment factor:


 

















Trending Tickers


/quotes/zigman/17636479/composite VUZI+15.60%


/quotes/zigman/237947/composite JCP-5.83%


/quotes/zigman/59392505/composite NUGT-2.93%


/quotes/zigman/59386294/composite JNUG-5.94%


/quotes/zigman/65801738/composite TLT+1.11%


X




Powered by














Log In




11:53 PM EDT
July 23, 2017


/marketstate/country/us
New York

	Closed


/marketstate/country/uk
London

	Closed


/marketstate/country/jp
Tokyo

	Open





/marketstate/country/us
 


/marketstate/country/uk
 


/marketstate/country/jp
 











View All



Latest News

/news/latest
11:22p‘Game of Thrones’: The four biggest takeaways from 'Stormborn’
11:09pWhy you’re more likely to die in an accident during the summer months
11:09pThese wealthy parents spend $20,000 for summer camps so their kids can be ‘normal’
11:07p5 totally avoidable reasons why millennials can’t have nice things (or save any money)
11:06pHow Elon Musk and shorter commutes could transform people’s lives
11:05pJohn McCain is a war hero — but think twice before saying he’s ‘battling’ cancer 
11:04pThe dark side of cruises
5:37pAt least 9 dead after overheated tractor-trailer found outside Texas Walmart
5:01p‘Full transparency’ doesn’t mean what Scaramucci apparently thinks it means
5:00pStocks brace for volatility in earnings deluge; Fed meeting looms
4:53pIf you suddenly quit your job like Sean Spicer, here’s what you should do next
4:52pNever (ever) say these things to a co-worker
4:51pMy uncle with dementia needs long-term care — should I refinance his house?
4:49pThis is the deadliest time of your life to put on weight
4:45pWhy house prices in gay neighborhoods are soaring
4:45pNearly 40% of adults don’t have life insurance — these startups are trying to change that
4:44pMarie Kondo says this one thing could be holding you back from falling in love
4:44pThis luxury credit card is only for truly big spenders
4:43pBanks have raised credit-card interest rates — but not savings account rates
12:13aHeavy showers swamp New Orleans street with rainwater
Loading more headlines...




dow

/quotes/zigman/627449/realtime
21,580.07

-31.71
-0.15%





nasdaq

/quotes/zigman/12633936/realtime
6,387.75

-2.25
-0.04%





s&p 500

/quotes/zigman/3870025/realtime
2,472.54

-0.91
-0.04%













Kiosk


1352872800000
1352872800000


The RetireMentors






				Retirement advice from our industry experts
				Our team of financial professionals can help you plan and save 
					for retirement, then 
				live well in it.



/conga/kiosk/retirementors.html
361307




1320411600000
1320616500000


Alerts



/conga/kiosk/alerts.html
310238




1333717800000
1333964100000


Virtual Stock Exchange





Our free stock-market game
				• Trade your virtual portfolio in real time
				• Talk strategies in group discussions
				• Find or create a game that suits you
				• Use our learning center to improve 



/conga/kiosk/games.html
310284




1245657600000
1277280000000


Location Scouts




Housing-market insights from our realty pros
																																																							Plus the latest data from Realtor.com on 21 home markets across the U.S.
• See our complete Real Estate site


/conga/kiosk/real_estate.html
357012




1404799200000
1404799200000


Lazy Portfolios





				Set it and forget it
				Check out the returns on our 8 Lazy Portfolios that are made up 
				of low-cost 
				buy-and-hold index funds.

				• How to create your own Lazy Portfolio


/conga/kiosk/lazy_portfolio.html
313134














MarketWatch.com




Site Index
Topics
Help
Feedback
Newsroom Roster

                    Media Archive
Premium Products
Mobile


Company Info
Code of Conduct
Corrections
Advertising Media Kit
Advertise Locally
Reprints & Licensing
Broker Center

                    Your Ad Choices


Follow MarketWatch


































RSS
Podcasts






WSJ.com
Barron's Online
BigCharts
Virtual Stock Exchange


Financial News London
WSJ.com Small Business
realtor.com
Mansion Global












		Copyright © 2017 MarketWatch, Inc.  All rights reserved.
		By using this site, you agree to the Terms of Service,
        Privacy Policy and Cookie Policy.
	



            Intraday Data provided by SIX Financial Information and subject to terms of use. Historical and current end-of-day data provided by SIX Financial Information. All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.
        






MarketWatch Top Stories
Link to MarketWatch's Slice.

15


























































    GTXI SEC Filings - GTx Inc. SEC Filings - MarketWatch




































Bulletin






Investor Alert







Tokyo Markets Close in:



Currencies
Europe Markets
London Markets


















Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close































GTx Inc.

                  NASDAQ: GTXI
          



GO



Set Alerts
Find a Broker




Join TD Ameritrade




Market Index


 

Overview
      
Profile
      
News
      
Charts
      
Financials
      
Historical Quotes
      
Analyst Estimates
      
Options
      
SEC Filings
      
Insiders
      


/marketstate/country/us

GTx Inc.



Market closed
 --Quotes are delayed by 20 min
Jul 21, 2017, 3:59 p.m.


GTXI

/quotes/zigman/81798317/composite


$
5.60




Change

-0.02
-0.36%

Volume
Volume 14,860
Quotes are delayed by 20 min








/quotes/zigman/81798317/composite
Previous close

$
			5.62
		


$
				5.60
			
Change

-0.02
-0.36%





Day low
Day high
$5.52
$5.66










52 week low
52 week high

            $2.73
        

            $11.19
        

















Show All


8-K



10-K



10-Q



Proxy



Registration



13D



13F



13G







SEC Filings for GTx Inc.
    
Getting Started with SEC Filings



Filing Date
Document Date
Type
Category
Amended



06/12/2017


06/12/2017


8-K


Special Events







05/15/2017


03/31/2017


10-Q


Quarterly Reports







05/15/2017


05/15/2017


8-K


Special Events







05/11/2017


05/11/2017


8-K


Special Events







05/03/2017


05/03/2017


8-K


Special Events







03/31/2017


05/11/2017


DEF 14A


Proxy Statement







03/24/2017


12/31/2016


10-K


Annual Reports







03/15/2017


03/15/2017


8-K


Special Events







02/14/2017


N/A


SC 13G/A


Institutional Ownership


*




02/02/2017


N/A


SC 13G/A


Institutional Ownership


*




01/09/2017


01/06/2017


8-K


Special Events







12/21/2016


12/20/2016


8-K


Special Events







12/08/2016


12/08/2016


8-K


Special Events







12/05/2016


12/05/2016


8-K


Special Events







12/01/2016


N/A


SC 13G/A


Institutional Ownership


*




11/28/2016


11/28/2016


8-K


Special Events







11/16/2016


11/16/2016


8-K


Special Events







11/07/2016


09/30/2016


10-Q


Quarterly Reports







11/03/2016


11/03/2016


8-K


Special Events







10/17/2016


N/A


SC 13D/A


N/A


*






More...





      SEC Filings provided by EDGAR Online, Inc.















Trending Tickers


/quotes/zigman/17636479/composite VUZI+15.60%


/quotes/zigman/237947/composite JCP-5.83%


/quotes/zigman/59392505/composite NUGT-2.93%


/quotes/zigman/65801738/composite TLT+1.11%


/quotes/zigman/59386294/composite JNUG-5.94%


X




Powered by














Log In




11:53 PM EDT
July 23, 2017


/marketstate/country/us
New York

	Closed


/marketstate/country/uk
London

	Closed


/marketstate/country/jp
Tokyo

	Open





/marketstate/country/us
 


/marketstate/country/uk
 


/marketstate/country/jp
 











View All



Latest News

/news/latest
11:22p‘Game of Thrones’: The four biggest takeaways from 'Stormborn’
11:09pWhy you’re more likely to die in an accident during the summer months
11:09pThese wealthy parents spend $20,000 for summer camps so their kids can be ‘normal’
11:07p5 totally avoidable reasons why millennials can’t have nice things (or save any money)
11:06pHow Elon Musk and shorter commutes could transform people’s lives
11:05pJohn McCain is a war hero — but think twice before saying he’s ‘battling’ cancer 
11:04pThe dark side of cruises
5:37pAt least 9 dead after overheated tractor-trailer found outside Texas Walmart
5:01p‘Full transparency’ doesn’t mean what Scaramucci apparently thinks it means
5:00pStocks brace for volatility in earnings deluge; Fed meeting looms
4:53pIf you suddenly quit your job like Sean Spicer, here’s what you should do next
4:52pNever (ever) say these things to a co-worker
4:51pMy uncle with dementia needs long-term care — should I refinance his house?
4:49pThis is the deadliest time of your life to put on weight
4:45pWhy house prices in gay neighborhoods are soaring
4:45pNearly 40% of adults don’t have life insurance — these startups are trying to change that
4:44pMarie Kondo says this one thing could be holding you back from falling in love
4:44pThis luxury credit card is only for truly big spenders
4:43pBanks have raised credit-card interest rates — but not savings account rates
12:13aHeavy showers swamp New Orleans street with rainwater
Loading more headlines...




dow

/quotes/zigman/627449/realtime
21,580.07

-31.71
-0.15%





nasdaq

/quotes/zigman/12633936/realtime
6,387.75

-2.25
-0.04%





s&p 500

/quotes/zigman/3870025/realtime
2,472.54

-0.91
-0.04%













Kiosk


1352872800000
1352872800000


The RetireMentors






				Retirement advice from our industry experts
				Our team of financial professionals can help you plan and save 
					for retirement, then 
				live well in it.



/conga/kiosk/retirementors.html
361307




1320411600000
1320616500000


Alerts



/conga/kiosk/alerts.html
310238




1333717800000
1333964100000


Virtual Stock Exchange





Our free stock-market game
				• Trade your virtual portfolio in real time
				• Talk strategies in group discussions
				• Find or create a game that suits you
				• Use our learning center to improve 



/conga/kiosk/games.html
310284




1245657600000
1277280000000


Location Scouts




Housing-market insights from our realty pros
																																																							Plus the latest data from Realtor.com on 21 home markets across the U.S.
• See our complete Real Estate site


/conga/kiosk/real_estate.html
357012




1404799200000
1404799200000


Lazy Portfolios





				Set it and forget it
				Check out the returns on our 8 Lazy Portfolios that are made up 
				of low-cost 
				buy-and-hold index funds.

				• How to create your own Lazy Portfolio


/conga/kiosk/lazy_portfolio.html
313134














MarketWatch.com




Site Index
Topics
Help
Feedback
Newsroom Roster

                    Media Archive
Premium Products
Mobile


Company Info
Code of Conduct
Corrections
Advertising Media Kit
Advertise Locally
Reprints & Licensing
Broker Center

                    Your Ad Choices


Follow MarketWatch


































RSS
Podcasts






WSJ.com
Barron's Online
BigCharts
Virtual Stock Exchange


Financial News London
WSJ.com Small Business
realtor.com
Mansion Global












		Copyright © 2017 MarketWatch, Inc.  All rights reserved.
		By using this site, you agree to the Terms of Service,
        Privacy Policy and Cookie Policy.
	



            Intraday Data provided by SIX Financial Information and subject to terms of use. Historical and current end-of-day data provided by SIX Financial Information. All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.
        






MarketWatch Top Stories
Link to MarketWatch's Slice.

15


























































Pipeline - GTx






































































 








Information Request
Contact
Careers
 

Search








Search:


 






PipelineOverview
Stress Urinary Incontinence
Breast Cancer
Duchenne Muscular Dystrophy
Prostate Cancer




PipelineNovember 23, 2015Dan CowperNovember 23, 2015 
Developing oral medicines based on hormone receptor targeting for patients in need.



Indication (Study Number)
Drug
Preclinical
Phase 1
Phase 2
Phase 3



Stress Urinary Incontinence



(G201001)
Enobosarm (SARM)


64%




Breast Cancer



ER+ / AR+ (G200801)
Enobosarm (SARM)


completed58%



ER+ / AR+ (G200802)
Enobosarm (SARM)


64%



AR+ TNBC (G200901)
Enobosarm (SARM)


64%



Duchenne Muscular Dystrophy
Preclinical
Candidate (SARM)


15%



Prostate Cancer
Preclinical
Candidate (SARD)


15%








Indication (Study Number)
Drug
Phase



Stress Urinary Incontinence



(G201001)
Enobosarm (SARM)
Ph2



Breast Cancer



ER+ / AR+ (G200801)
Enobosarm (SARM)
Ph2


ER+ / AR+ (G200802)
Enobosarm (SARM)
Ph2


AR+ TNBC (G200901)
Enobosarm (SARM)
Ph2


Duchenne Muscular Dystrophy
Preclinical
Candidate (SARM)
PreClin


Prostate Cancer
Preclinical
Candidate (SARD)
PreClin





















				MENU							



About

Overview
Management Team
Board of Directors
Careers
Contact


Pipeline

Overview
Stress Urinary Incontinence
Breast Cancer
Duchenne Muscular Dystrophy
Prostate Cancer


Diseases

Overview
Stress Urinary Incontinence
Breast Cancer
Duchenne Muscular Dystrophy
Prostate Cancer


Science

Overview
Selective Androgen Receptor Modulator (SARM)

The Potential Advantage of SARMs
SARMs in Breast Cancer
SARMs in Muscle Diseases
SARMs in Urology


Selective Androgen Receptor Degrader (SARD)


Investors

Overview
News Releases
Events & Presentations
Financial Reports

SEC Filings


Stock Information

Historic Stock Lookup
Investment Calculator
Analyst Coverage


Corporate Governance

Management
Board of Directors
Committee Composition


Investor FAQs
IRS Form 8937
Contact Us




 






GTx, Inc. - Product Pipeline Review - 2016































| Compare 
About Us | 
Contact Us






Home
Research Category
Publisher List
Custom Research
Cart
Compare



Research Category
User Guide
Policies
Contact Us
About us
Site Map











Home > Market Research Report  > Pharmaceutical > Pharmaceutical Companies > Pharma Info









Market Research Report
GTx, Inc. - Product Pipeline Review - 2016



Published by
Global Markets Direct
Product code
192614


Published
May 25, 2016
Content info
47 Pages 


Price








USD 1500

PDF by E-mail (Single user license)





USD 3000

PDF by E-mail (Site license)





USD 4500

PDF by E-mail (Global license)
























GTx, Inc. - Product Pipeline Review - 2016



Published: May 25, 2016
Content info: 47 Pages














Description

Summary
Global Markets Direct's, 'GTx, Inc. - Product Pipeline Review - 2016', provides an overview of the GTx, Inc.'s pharmaceutical research and development focus.
The report provides comprehensive information on the therapeutics under development by GTx, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.
Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope

 The report provides a snapshot of the pipeline therapeutic landscape of GTx, Inc.
 The report provides overview of GTx, Inc. including its business description, key facts, and locations and subsidiaries
 The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
 The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
 The report assesses GTx, Inc.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
 The report features GTx, Inc.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

 Evaluate GTx, Inc.'s strategic position with total access to detailed information on its product pipeline
 Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
 Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
 Identify and understand important and diverse types of therapeutics under development for GTx, Inc.
 Identify potential new clients or partners in the target demographic
 Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
 Devise corrective measures for pipeline projects by understanding GTx, Inc.'s pipeline depth and focus of pipeline therapeutics
 Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope




Table of Contents
Product Code: GMDHC08053CDBTable of Contents

Table of Contents 

List of Tables 
List of Figures 

GTx, Inc. Snapshot 

GTx, Inc. Overview 
Key Information 
Key Facts 

GTx, Inc. - Research and Development Overview 

Key Therapeutic Areas 

GTx, Inc. - Pipeline Review 

Pipeline Products by Stage of Development 
Pipeline Products - Monotherapy 

GTx, Inc. - Pipeline Products Glance 

GTx, Inc. - Clinical Stage Pipeline Products 

Phase II Products/Combination Treatment Modalities 

GTx, Inc. - Early Stage Pipeline Products 

Preclinical Products/Combination Treatment Modalities 


GTx, Inc. - Drug Profiles 

enobosarm 

Product Description 
Mechanism of Action 
R&D Progress

GTx-758 

Product Description 
Mechanism of Action 
R&D Progress

Beta-LGND2 

Product Description 
Mechanism of Action 
R&D Progress

GTx-026 

Product Description 
Mechanism of Action 
R&D Progress

Gtx-027 

Product Description 
Mechanism of Action 
R&D Progress

Gtx-186 

Product Description 
Mechanism of Action 
R&D Progress

Gtx-230 

Product Description 
Mechanism of Action 
R&D Progress

GTx-878 

Product Description 
Mechanism of Action 
R&D Progress

Small Molecules to Antagonize Androgen Receptor for Metastatic Castration Resistant Prostate Cancer 

Product Description 
Mechanism of Action 
R&D Progress

Small Molecules to Inhibit AKR1C3 for Prostate Cancer and Castration Resistant Prostate Cancer 

Product Description 
Mechanism of Action 
R&D Progress

Small Molecules to Inhibit Tubulin for Cancer 

Product Description 
Mechanism of Action 
R&D Progress


GTx, Inc. - Pipeline Analysis 

GTx, Inc. - Pipeline Products by Target 
GTx, Inc. - Pipeline Products by Route of Administration 
GTx, Inc. - Pipeline Products by Molecule Type 
GTx, Inc. - Pipeline Products by Mechanism of Action 

GTx, Inc. - Recent Pipeline Updates 
GTx, Inc. - Dormant Projects 
GTx, Inc. - Discontinued Pipeline Products 

Discontinued Pipeline Product Profiles 

toremifene citrate 


GTx, Inc. - Company Statement 
GTx, Inc. - Locations And Subsidiaries 

Head Office 

Appendix 

Methodology 
Coverage 
Secondary Research 
Primary Research 
Expert Panel Validation 
Contact Us 
Disclaimer 


List of Tables

GTx, Inc., Key Information 
GTx, Inc., Key Facts 
GTx, Inc. - Pipeline by Indication, 2016 
GTx, Inc. - Pipeline by Stage of Development, 2016 
GTx, Inc. - Monotherapy Products in Pipeline, 2016 
GTx, Inc. - Phase II, 2016 
GTx, Inc. - Preclinical, 2016 
GTx, Inc. - Pipeline by Target, 2016 
GTx, Inc. - Pipeline by Route of Administration, 2016 
GTx, Inc. - Pipeline by Molecule Type, 2016 
GTx, Inc. - Pipeline Products by Mechanism of Action, 2016 
GTx, Inc. - Recent Pipeline Updates, 2016 
GTx, Inc. - Dormant Developmental Projects,2016 
GTx, Inc. - Discontinued Pipeline Products, 2016 

List of Figures

GTx, Inc. - Pipeline by Top 10 Indication, 2016 
GTx, Inc. - Pipeline by Stage of Development, 2016 
GTx, Inc. - Monotherapy Products in Pipeline, 2016 
GTx, Inc. - Pipeline by Target, 2016 
GTx, Inc. - Pipeline by Route of Administration, 2016 
GTx, Inc. - Pipeline by Molecule Type, 2016 
GTx, Inc. - Pipeline Products by Mechanism of Action, 2016 








Phone


Int'l: +1-860-674-8796
TollFree(US): +1-866-353-3335
Europe: +32-2-535-7543
Asia: +65-6223-2436


New for 2017 !

GII now purchases any market research reports from any publishers for you.  
			With noextra cost.
Contact us for more details.

FAQ


Delivery Time
User License
Payment Options
Compare Multiple Reports
















About
Contact
User Guide
Policies
Site Map



© Copyright 1997-2017, Global Information, Inc. All rights reserved.











GTx, Inc. - Product Pipeline Review - 2014























































  info@wiseguyreports.com  |   
 Chat with us   |    +1 (339) 368 6938 (US)  |     +44 208 133 9349 (UK) 



 Login    Register 






















Home


Report Categories







Premium Reports

Access to 600000+ Premium Reports











  
                                Aerospace & Defense
                              









  
                                Agri & Food
                              









  
                                Automotive
                              









  
                                Basic Materials
                              











  
                                Consumer Goods & Retail
                              









  
                                Energy
                              









  
                                Life Sciences
                              









  
                                Manufacturing & Construction
                              











  
                                Services
                              









  
                                Telecom & IT
                              









  
                                Education
                              









  
                                Security & Intelligence Systems
                              











  
                                Technology
                              









  
                                Company Reports
                              










Report Categories 










Aerospace & Defense
                





Agri & Food
                





Automotive
                





Basic Materials
                







Consumer Goods & Retail
                





Energy
                





Life Sciences
                





Manufacturing & Construction
                







Services
                





Telecom & IT
                





Education
                





Security & Intelligence Systems
                







Technology
                





Company Reports
                








Publisher
Knowledgestore

Countries 
              


Browse by Country
Browse by Continent
Browse by Group / Region



 Conferences
              


Upcoming Conferences
Seminars




 Conferences
              


Upcoming Conferences
Seminars




Countries 

Browse by Country
Browse by Continent
Browse by Group / Region



News & Blog

 Press Release
Blog



News & Blogs

 Press Release
Blogs


FAQs

About Us

About Our Company
Our Team
Life At WGR


Careers
Contact Us











                                         There are no items currently in your basket.
                                     













There are no items currently in your basket!














  




































Search 
                






 














Home
All Reports
GTx, Inc. - Product Pipeline Review - 2014









 


  GTx, Inc. - Product Pipeline Review - 2014


WGR10780
30 
                  April, 2014 
Global
50 pages 
Global Markets Direct






















Description




Table of Content




Sample Report




Enquiry before buy




Related Reports





GTx, Inc. - Product Pipeline Review - 2014SummaryGlobal Markets Direct’s, ‘GTx, Inc. - Product Pipeline Review - 2014’, provides an overview of the GTx, Inc.’s pharmaceutical research and development focus.This report provides comprehensive information on the current therapeutic developmental pipeline of GTx, Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.Scope- The report provides brief overview of GTx, Inc. including business description, key information and facts, and its locations and subsidiaries- The report reviews current pipeline of GTx, Inc.’s human therapeutic division and enlists all their major and minor projects- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones - Special feature on out-licensed and partnered product portfolio- The report summarizes all the dormant and discontinued pipeline projects- Latest company statement - Latest news and deals relating to the GTx, Inc.’s pipeline productsReasons to buy- Evaluate GTx, Inc.’s strategic position with total access to detailed information on its product pipeline- Assess the growth potential of GTx, Inc. in its therapy areas of focus- Identify new drug targets and therapeutic classes in the GTx, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps- Develop strategic initiatives by understanding the focus areas of GTx, Inc. and exploit collaboration and partnership opportunities- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage- Plan mergers and acquisitions effectively by identifying the most promising pipeline of GTx, Inc.- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope- Explore the dormant and discontinued projects of GTx, Inc. and identify potential opportunities in those areas- Avoid Intellectual Property Rights related issues


Table of ContentsTable of Contents 2List of Tables 4List of Figures 4GTx, Inc. Snapshot 5GTx, Inc. Overview 5Key Information 5Key Facts 5GTx, Inc. - Research and Development Overview 6Key Therapeutic Areas 6GTx, Inc. - Pipeline Review 9Pipeline Products by Stage of Development 9Pipeline Products - Monotherapy 10GTx, Inc. - Pipeline Products Glance 11GTx, Inc. - Late Stage Pipeline Products 11Phase III Products/Combination Treatment Modalities 11GTx, Inc. - Clinical Stage Pipeline Products 12Phase II Products/Combination Treatment Modalities 12Phase I Products/Combination Treatment Modalities 13GTx, Inc. - Early Stage Pipeline Products 14Preclinical Products/Combination Treatment Modalities 14GTx, Inc. - Drug Profiles 15enobosarm 15Product Description 15Mechanism of Action 15R&D Progress 15GTx-758 17Product Description 17Mechanism of Action 17R&D Progress 17Gtx-027 18Product Description 18Mechanism of Action 18R&D Progress 18Beta-LGND2 19Product Description 19Mechanism of Action 19R&D Progress 19Gtx-186 21Product Description 21Mechanism of Action 21R&D Progress 21Gtx-230 22Product Description 22Mechanism of Action 22R&D Progress 22Small Molecule to Inhibit AKR1C3 for Prostate Cancer 23Product Description 23Mechanism of Action 23R&D Progress 23Small Molecule to Inhibit Tubulin for Cancer 24Product Description 24Mechanism of Action 24R&D Progress 24GTx, Inc. - Pipeline Analysis 25GTx, Inc. - Pipeline Products by Target 25GTx, Inc. - Pipeline Products by Route of Administration 27GTx, Inc. - Pipeline Products by Molecule Type 28GTx, Inc. - Pipeline Products by Mechanism of Action 29GTx, Inc. - Recent Pipeline Updates 31GTx, Inc. - Dormant Projects 40GTx, Inc. - Discontinued Pipeline Products 41Discontinued Pipeline Product Profiles 41GTx-758 41toremifene citrate 41GTx, Inc. - Company Statement 42GTx, Inc. - Locations And Subsidiaries 48Head Office 48Appendix 49Methodology 49Coverage 49Secondary Research 49Primary Research 49Expert Panel Validation 49Contact Us 50Disclaimer 50List of TablesGTx, Inc., Key Information 5GTx, Inc., Key Facts 5GTx, Inc. - Pipeline by Indication, 2014 8GTx, Inc. - Pipeline by Stage of Development, 2014 9GTx, Inc. - Monotherapy Products in Pipeline, 2014 10GTx, Inc. - Phase III, 2014 11GTx, Inc. - Phase II, 2014 12GTx, Inc. - Phase I, 2014 13GTx, Inc. - Preclinical, 2014 14GTx, Inc. - Pipeline by Target, 2014 26GTx, Inc. - Pipeline by Route of Administration, 2014 27GTx, Inc. - Pipeline by Molecule Type, 2014 28GTx, Inc. - Pipeline Products by Mechanism of Action, 2014 30GTx, Inc. - Recent Pipeline Updates, 2014 31GTx, Inc. - Dormant Developmental Projects,2014 40GTx, Inc. - Discontinued Pipeline Products, 2014 41List of FiguresGTx, Inc. - Pipeline by Top 10 Indication, 2014 7GTx, Inc. - Pipeline by Stage of Development, 2014 9GTx, Inc. - Monotherapy Products in Pipeline, 2014 10GTx, Inc. - Pipeline by Top 10 Target, 2014 25GTx, Inc. - Pipeline by Top 10 Route of Administration, 2014 27GTx, Inc. - Pipeline by Top 10 Molecule Type, 2014 28GTx, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2014 29







                                Request a Sample Report
                                




Name:*










Email:*


(Optional: Request you to please fill in your Corporate Email-ID)



Job Title:*





Company:*





Phone No:*





Your Country:*

--select country--
Afghanistan
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antigua & Barbuda
Argentina
Armenia
Aruba
Australia
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia
Bosnia & Herzegovina
Botswana
Brazil
Brunei
Bulgaria
Burkina Faso
Burundi
Cambodja
Cameroon
Canada
Cape Verde
Cayman Islands
Central African Republic
Chad
Chile
China
Colombia
Comoros
Congo-Brazzaville
Congo-Kinshasa
Cook Islands
Costa Rica
Cote d"Ivoire
Croatia
Cuba
Cyprus
Czech Republic
Denmark
Djibouti
Dominica
Dominican Republic
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Falkland (Malvinas)
Faroes
Fiji
Finland
France
French-Guiana
Tahiti(French Polinesia)
Gabon
Gambia
Georgia
Germany
Ghana
Gibraltar
Greece
Greenland
Grenada
Guadeloupe
Guam
Guatemala
Guinea
Guinea-Bissau
Guyana
Haiti
Vatican City
Honduras
Hong Kong
Hungary
Iceland
India
Indonesia
Iran
Iraq
Ireland
Israel
Italy
Jamaica
Japan
Jordan
Kazakhstan
Kenya
Kiribati
North Korea
South Korea
Kuwait
Kyrgyzstan
Laos
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macao
Macedonia
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique
Mauritania
Mauritius
Mexico
Micronesia
Moldova
Monaco
Mongolia
Montserrat
Morocco
Mozambique
Myanmar
Namibia
Nauru
Nepal
Netherlands
Netherlands Antilles
New Caledonia
New Zealand
Nicaragua
Niger
Nigeria
Norfolk
Northern Mariana
Norway
Oman
Pakistan
Palau
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn
Poland
Portugal
Puerto Rico
Qatar
Reunion
Romania
Russian Federation
Rwanda
Saint Helena
Saint Lucia
Saint Pierre and Miquelon
St Vincent & the Grenadines
Samoa
San Marino
Sao Tome & Principe
Saudi Arabia
Senegal
Seychelles
Sierra Leone
Singapore
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
Spain
Sri Lanka
Sudan
Suriname
Svalbard and Jan Mayen
Swaziland
Sweden
Switzerland
Syria
Taiwan
Tajikistan
Tanzania
Thailand
Togo
Tokelau
Tonga
Trinidad & Tobago
Tunisia
Turkey
Turkmenistan
Turks and Caicos Islands
Tuvalu
Uganda
Ukraine
United Arab Emirates
United Kingdom
United States of America
Uruguay
Uzbekistan
Vanuatu
Venezuela
Viet Nam
Virgin Islands British
Virgin Islands US
Wales
Western Sahara
Yemen
Zambia
Zimbabwe
Timor-Leste
Curacao
St Kitts & Nevis
Sint Maarten
Guernsey
Isle of Man
Jersey
Niue
Montenegro



Do you have any Specific field of Interest?*

















Confirm


 








Make an enquiry before buying this Report




Name:*










Email:*


(Optional: Request you to please fill in your Corporate Email-ID)



Job Title:*





Company:*





Phone No:*





Your Country:*

--select country--
Afghanistan
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antigua & Barbuda
Argentina
Armenia
Aruba
Australia
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia
Bosnia & Herzegovina
Botswana
Brazil
Brunei
Bulgaria
Burkina Faso
Burundi
Cambodja
Cameroon
Canada
Cape Verde
Cayman Islands
Central African Republic
Chad
Chile
China
Colombia
Comoros
Congo-Brazzaville
Congo-Kinshasa
Cook Islands
Costa Rica
Cote d"Ivoire
Croatia
Cuba
Cyprus
Czech Republic
Denmark
Djibouti
Dominica
Dominican Republic
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Falkland (Malvinas)
Faroes
Fiji
Finland
France
French-Guiana
Tahiti(French Polinesia)
Gabon
Gambia
Georgia
Germany
Ghana
Gibraltar
Greece
Greenland
Grenada
Guadeloupe
Guam
Guatemala
Guinea
Guinea-Bissau
Guyana
Haiti
Vatican City
Honduras
Hong Kong
Hungary
Iceland
India
Indonesia
Iran
Iraq
Ireland
Israel
Italy
Jamaica
Japan
Jordan
Kazakhstan
Kenya
Kiribati
North Korea
South Korea
Kuwait
Kyrgyzstan
Laos
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macao
Macedonia
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique
Mauritania
Mauritius
Mexico
Micronesia
Moldova
Monaco
Mongolia
Montserrat
Morocco
Mozambique
Myanmar
Namibia
Nauru
Nepal
Netherlands
Netherlands Antilles
New Caledonia
New Zealand
Nicaragua
Niger
Nigeria
Norfolk
Northern Mariana
Norway
Oman
Pakistan
Palau
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn
Poland
Portugal
Puerto Rico
Qatar
Reunion
Romania
Russian Federation
Rwanda
Saint Helena
Saint Lucia
Saint Pierre and Miquelon
St Vincent & the Grenadines
Samoa
San Marino
Sao Tome & Principe
Saudi Arabia
Senegal
Seychelles
Sierra Leone
Singapore
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
Spain
Sri Lanka
Sudan
Suriname
Svalbard and Jan Mayen
Swaziland
Sweden
Switzerland
Syria
Taiwan
Tajikistan
Tanzania
Thailand
Togo
Tokelau
Tonga
Trinidad & Tobago
Tunisia
Turkey
Turkmenistan
Turks and Caicos Islands
Tuvalu
Uganda
Ukraine
United Arab Emirates
United Kingdom
United States of America
Uruguay
Uzbekistan
Vanuatu
Venezuela
Viet Nam
Virgin Islands British
Virgin Islands US
Wales
Western Sahara
Yemen
Zambia
Zimbabwe
Timor-Leste
Curacao
St Kitts & Nevis
Sint Maarten
Guernsey
Isle of Man
Jersey
Niue
Montenegro



Your Enquiry*

















Confirm


 
















Purchase this Market Research Report







 USD




 GBP




 EURO




 YEN




 INR







                        1-user PDF
                         
                          $1,500.00
                        

 
                        Site PDF 
                         
                          $3,000.00
                        

 
                        Enterprise PDF 
                         
                          $4,500.00
                        





  1-user PDF
  
 
    1,152.60
   

 
  Site PDF 
  
 
  2,305.20
  

 
  Enterprise PDF 
  
 
  3,457.80
  





  1-user PDF
  
 
    1,284.90
   

 
  Site PDF 
  
 
  2,569.80
  

 
  Enterprise PDF 
  
 
  3,854.70
  





  1-user PDF
  
 
    166,474.50
   

 
  Site PDF 
  
 
  332,949.00
  

 
  Enterprise PDF 
  
 
  499,423.50
  





  1-user PDF
  
 
    96,637.50
   

 
  Site PDF 
  
 
  193,275.00
  

 
  Enterprise PDF 
  
 
  289,912.50
  









Add To Cart
BUY NOW





 















  Email Report


  Sample Report




  Save Page


  Any Questions




  Download information


  Check Discount




  Download Order Form









  Email Report


  Sample Report




  Save Page


  Any Questions




  Download information


  Check Discount




  Download Order Form






Contact Us










Akash Anand
Domain Head Business Development
sales@wiseguyreports.com
+1 (646) 843 9312 (US)
+44 208 133 9349 (UK)













Rishabh Arora
Domain Head Business Development
sales@wiseguyreports.com
+44-208-133-9346













Abu Koshy
Domain Head Business Development
sales@wiseguyreports.com
+1 339 368 6938










Related Reports








                  ×
              
Tell a friend about this report 




Your Name:*





Your Email:*





Friend's Name:*





Friend's Email:*





Your Enquiry*









Send


 







































    GTXI News - GTx Inc. Company News & Press Releases - MarketWatch




































Bulletin






Investor Alert







Tokyo Markets Close in:



Currencies
Europe Markets
London Markets


















Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close































GTx Inc.

                  NASDAQ: GTXI
          



GO



Set Alerts
Find a Broker




Join TD Ameritrade




Market Index


 

Overview
      
Profile
      
News
      
Charts
      
Financials
      
Historical Quotes
      
Analyst Estimates
      
Options
      
SEC Filings
      
Insiders
      


/marketstate/country/us

GTx Inc.



Market closed
 --Quotes are delayed by 20 min
Jul 21, 2017, 3:59 p.m.


GTXI

/quotes/zigman/81798317/composite


$
5.60




Change

-0.02
-0.36%

Volume
Volume 14,860
Quotes are delayed by 20 min








/quotes/zigman/81798317/composite
Previous close

$
			5.62
		


$
				5.60
			
Change

-0.02
-0.36%





Day low
Day high
$5.52
$5.66










52 week low
52 week high

            $2.73
        

            $11.19
        

















/news/latest/company/us/gtxi

      MarketWatch News on GTXI
    





California doctors charged with insider trading after drug tests halted

3:59 p.m. May 19, 2014
 - Russ Britt




 Tuesday’s biggest gaining and declining stocks
4:54 p.m. May 8, 2012
 - MarketWatch




 GTX rallies 12% on FDA update
1:17 p.m. May 8, 2012
 - Val Brickates Kennedy




 GTx: FDA lifts hold on Capesaris trials
7:27 a.m. May 8, 2012
 - MarketWatch.com




 GTx Inc. up 27% in premarket
8:01 a.m. May 7, 2012
 - Steve Gelsi




 Gtx responds to FDA halt on Capesaris trial
7:24 a.m. April 4, 2012
 - MarketWatch.com




 Tuesday’s biggest gaining & declining stocks
6:19 p.m. Feb. 21, 2012
 - Kate Gibson




 Gtx: FDA halts Capesaris trials on blood-clot risk
8:47 a.m. Feb. 21, 2012
 - MarketWatch.com




 Monday’s biggest gaining and declining stocks
5:48 p.m. Jan. 30, 2012
 - Kate Gibson




 GTX soars 35% on analyst upgrade reports
12:31 p.m. Jan. 30, 2012
 - Val Brickates Kennedy




 GTX gains on analyst rating
12:05 p.m. July 20, 2011
 - Val Brickates Kennedy





Carpenter, Molycorp, Office Depot among gainers

11:03 a.m. June 20, 2011
 - Tom Bemis





Ten gainers in Wednesday's market

10:46 a.m. June 8, 2011
 - Craig Tolliver




 Wednesday’s biggest gaining and declining stocks
5:32 p.m. April 13, 2011
 - William Spain




 Drug stocks inch higher in afternoon trading
3:30 p.m. April 13, 2011
 - Val Brickates Kennedy




 GTx rockets on analyst upgrade
10:03 a.m. April 13, 2011
 - Val Brickates Kennedy




 GTX falls in drug-stock trading
3:27 p.m. March 2, 2011
 - Val Brickates Kennedy




 Amylin, Illumina gain; drug indexes slip
11:50 a.m. Oct. 27, 2010
 - Val Brickates Kennedy




 Wednesday's biggest gaining and declining stocks
2:00 p.m. May 26, 2010
 - MarketWatch




 Drug stocks rebound; GTx sinks on failed study
10:46 a.m. May 26, 2010
 - Val Brickates Kennedy


Loading more headlines...









/news/nonmarketwatch/company/us/gtxi

      Other News on GTXI
    





GTx's (GTXI) Enobosarm Positive in Phase II Study; Shares Up

10:14 a.m. June 13, 2017
 - Zacks.com





Premarket Gainers as of 9:05 am

9:18 a.m. June 12, 2017
 - Seeking Alpha





GTx's enobosarm shows treatment effect in mid-stage study in postmenopausal women with stress urinary incontinence; shares up 14% premarket

8:03 a.m. June 12, 2017
 - Seeking Alpha





Hottest Manufacturing Stocks Now – NEON TPIV GTXI BMRA

5:30 p.m. Dec. 12, 2016
 - InvestorPlace.com





Hottest Manufacturing Stocks Now – EBS ACIU VCEL OPHT

12:00 p.m. Dec. 9, 2016
 - InvestorPlace.com





GTx's enobosarm shows treatment benefit at 24 weeks in mid-stage breast cancer study

11:43 a.m. Dec. 8, 2016
 - Seeking Alpha





GTX's enobosarm successful in mid-stage breast cancer study; shares up 4%

10:36 a.m. Nov. 28, 2016
 - Seeking Alpha





GTx (GTXI) Investor Presentation - Slideshow

3:31 p.m. Nov. 18, 2016
 - Seeking Alpha





Stage 1 milestone met in GTx's mid-stage study of lead product candidate in certain type of breast cancer, trial to advance to Stage 2

8:43 a.m. Nov. 16, 2016
 - Seeking Alpha




 10-Q: GTX INC /DE/
6:26 p.m. Nov. 7, 2016
 - Edgar Online -  (EDG = 10Q, 10K)





Insider Invests in GTx

4:27 p.m. Oct. 18, 2016
 - GuruFocus.com





GTx's enobosarm shows positive results in mid-stage breast cancer study; shares up 47%

1:32 p.m. Sept. 8, 2016
 - Seeking Alpha




 10-Q: GTX INC /DE/
6:58 p.m. Aug. 9, 2016
 - Edgar Online -  (EDG = 10Q, 10K)





GTx (GTXI) Shows Strength: Stock Adds 11.2% in Session

8:15 a.m. June 21, 2016
 - Zacks.com





GTx's (GTXI) CEO Marc Hanover on Q4 2015 Results - Earnings Call Transcript

11:21 a.m. March 3, 2016
 - Seeking Alpha





GTx reports Q4 and FY15 results

10:22 a.m. March 3, 2016
 - Seeking Alpha





GTx (GTXI) Q4 2015 Results - Earnings Call Webcast

9:55 a.m. March 3, 2016
 - Seeking Alpha





Strength Seen in GTX (GTXI): Stock Adds 7.8% in Session

9:20 a.m. Dec. 16, 2015
 - Zacks.com





GTx's (GTXI) CEO Marc Hanover on Q3 2015 Results - Earnings Call Transcript

10:16 a.m. Oct. 29, 2015
 - Seeking Alpha





GTx (GTXI) Q3 2015 Results - Earnings Call Webcast

8:55 a.m. Oct. 29, 2015
 - Seeking Alpha


Loading more headlines...







/news/pressrelease/company/us/gtxi

      Press Releases on GTXI
    




 GTx Discusses Key Goals with WSA
1:43 p.m. July 12, 2017
 - Marketwired




 Pharma and Biotech Companies Significantly Investing in R&D, Focus on Rising Demand for Advanced Medicines
8:45 a.m. June 13, 2017
 - PR Newswire - PRF




 Today's Research Reports on Stocks to Watch: Xbiotech and GTx
8:12 a.m. June 13, 2017
 - ACCESSWIRE




 GTx Announces Positive Preliminary Results from Ongoing Phase 2 
      Proof-of-Concept Clinical Trial in Women with Stress Urinary Incontinence
7:00 a.m. June 12, 2017
 - BusinessWire - BZX




 GTx Provides Corporate Update and Reports First Quarter 2017 
      Financial Results
7:00 a.m. May 15, 2017
 - BusinessWire - BZX




 GTx Announces Acceptance of an Abstract on Preliminary Results from 
      Phase 2 Clinical Trial in Women with Stress Urinary Incontinence at the 
      International Continence Society Annual Meeting
7:00 a.m. May 11, 2017
 - BusinessWire - BZX




 GTx Announces Results from Preclinical Studies of SARMs in Duchenne 
      Muscular Dystrophy Models Published in Human Molecular Genetics
7:00 a.m. May 3, 2017
 - BusinessWire - BZX




 GTx Provides Corporate Update and Reports Fourth Quarter and Year-End 
      2016 Financial Results
7:00 a.m. March 15, 2017
 - BusinessWire - BZX




 GTx, Inc. to Report Fourth Quarter and Full Year 2016 Financial 
      Results on March 15, 2017
8:00 a.m. March 7, 2017
 - BusinessWire - BZX




 GTx Reports Results from Ongoing Enobosarm Phase 2 Clinical Trial in 
      ER+/AR+ Breast Cancer
8:00 a.m. Dec. 8, 2016
 - BusinessWire - BZX




 GTx, Inc. Announces 1-for-10 Reverse Stock Split
10:37 a.m. Dec. 5, 2016
 - BusinessWire - BZX




 Enobosarm Meets Pre-Specified Primary Efficacy Endpoint in Ongoing 
      Phase 2 Clinical Trial in ER+/AR+ Breast Cancer
8:00 a.m. Nov. 28, 2016
 - BusinessWire - BZX




 GTx Announces Webcast of Corporate Presentation at the 28th 
      Annual Piper Jaffray Healthcare Conference
8:00 a.m. Nov. 23, 2016
 - BusinessWire - BZX




 Blog Coverage GTx Inc. Enobosarm Achieves Stage 1 Milestone
9:15 a.m. Nov. 17, 2016
 - ACCESSWIRE




 GTx Achieves Second Stage 1 Milestone in Phase 2 Clinical Trial of 
      Enobosarm in ER+/AR+ Breast Cancer
8:00 a.m. Nov. 16, 2016
 - BusinessWire - BZX




 GTx Announces Webcast of Corporate Presentation at the Stifel 2016 
      Healthcare Conference
8:00 a.m. Nov. 11, 2016
 - BusinessWire - BZX




 GTx Provides Corporate Update and Reports Third Quarter 2016 
      Financial Results
7:00 a.m. Nov. 3, 2016
 - BusinessWire - BZX




 Significant Investor Maintains Vote Against Proposed Merger of Female Health Company with Aspen Park Pharmaceuticals
8:00 a.m. Oct. 21, 2016
 - ACCESSWIRE




 GTx Announces $14.0 Million Registered Direct Common Stock Offering
7:00 a.m. Oct. 12, 2016
 - BusinessWire - BZX




 GTx Achieves Stage 1 Milestone in Phase 2 Clinical Trial of Enobosarm 
      in ER+/AR+ Breast Cancer
7:00 a.m. Sept. 8, 2016
 - BusinessWire - BZX


Loading more headlines...


















Trending Tickers


/quotes/zigman/17636479/composite VUZI+15.60%


/quotes/zigman/237947/composite JCP-5.83%


/quotes/zigman/59392505/composite NUGT-2.93%


/quotes/zigman/59386294/composite JNUG-5.94%


/quotes/zigman/65801738/composite TLT+1.11%


X




Powered by














Log In




11:53 PM EDT
July 23, 2017


/marketstate/country/us
New York

	Closed


/marketstate/country/uk
London

	Closed


/marketstate/country/jp
Tokyo

	Open





/marketstate/country/us
 


/marketstate/country/uk
 


/marketstate/country/jp
 











View All



Latest News

/news/latest
11:22p‘Game of Thrones’: The four biggest takeaways from 'Stormborn’
11:09pWhy you’re more likely to die in an accident during the summer months
11:09pThese wealthy parents spend $20,000 for summer camps so their kids can be ‘normal’
11:07p5 totally avoidable reasons why millennials can’t have nice things (or save any money)
11:06pHow Elon Musk and shorter commutes could transform people’s lives
11:05pJohn McCain is a war hero — but think twice before saying he’s ‘battling’ cancer 
11:04pThe dark side of cruises
5:37pAt least 9 dead after overheated tractor-trailer found outside Texas Walmart
5:01p‘Full transparency’ doesn’t mean what Scaramucci apparently thinks it means
5:00pStocks brace for volatility in earnings deluge; Fed meeting looms
4:53pIf you suddenly quit your job like Sean Spicer, here’s what you should do next
4:52pNever (ever) say these things to a co-worker
4:51pMy uncle with dementia needs long-term care — should I refinance his house?
4:49pThis is the deadliest time of your life to put on weight
4:45pWhy house prices in gay neighborhoods are soaring
4:45pNearly 40% of adults don’t have life insurance — these startups are trying to change that
4:44pMarie Kondo says this one thing could be holding you back from falling in love
4:44pThis luxury credit card is only for truly big spenders
4:43pBanks have raised credit-card interest rates — but not savings account rates
12:13aHeavy showers swamp New Orleans street with rainwater
Loading more headlines...




dow

/quotes/zigman/627449/realtime
21,580.07

-31.71
-0.15%





nasdaq

/quotes/zigman/12633936/realtime
6,387.75

-2.25
-0.04%





s&p 500

/quotes/zigman/3870025/realtime
2,472.54

-0.91
-0.04%













Kiosk


1352872800000
1352872800000


The RetireMentors






				Retirement advice from our industry experts
				Our team of financial professionals can help you plan and save 
					for retirement, then 
				live well in it.



/conga/kiosk/retirementors.html
361307




1320411600000
1320616500000


Alerts



/conga/kiosk/alerts.html
310238




1333717800000
1333964100000


Virtual Stock Exchange





Our free stock-market game
				• Trade your virtual portfolio in real time
				• Talk strategies in group discussions
				• Find or create a game that suits you
				• Use our learning center to improve 



/conga/kiosk/games.html
310284




1245657600000
1277280000000


Location Scouts




Housing-market insights from our realty pros
																																																							Plus the latest data from Realtor.com on 21 home markets across the U.S.
• See our complete Real Estate site


/conga/kiosk/real_estate.html
357012




1404799200000
1404799200000


Lazy Portfolios





				Set it and forget it
				Check out the returns on our 8 Lazy Portfolios that are made up 
				of low-cost 
				buy-and-hold index funds.

				• How to create your own Lazy Portfolio


/conga/kiosk/lazy_portfolio.html
313134














MarketWatch.com




Site Index
Topics
Help
Feedback
Newsroom Roster

                    Media Archive
Premium Products
Mobile


Company Info
Code of Conduct
Corrections
Advertising Media Kit
Advertise Locally
Reprints & Licensing
Broker Center

                    Your Ad Choices


Follow MarketWatch


































RSS
Podcasts






WSJ.com
Barron's Online
BigCharts
Virtual Stock Exchange


Financial News London
WSJ.com Small Business
realtor.com
Mansion Global












		Copyright © 2017 MarketWatch, Inc.  All rights reserved.
		By using this site, you agree to the Terms of Service,
        Privacy Policy and Cookie Policy.
	



            Intraday Data provided by SIX Financial Information and subject to terms of use. Historical and current end-of-day data provided by SIX Financial Information. All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.
        






MarketWatch Top Stories
Link to MarketWatch's Slice.

15





























































GTx, Inc. - Product Pipeline Review - 2016























































  info@wiseguyreports.com  |   
 Chat with us   |    +1 (339) 368 6938 (US)  |     +44 208 133 9349 (UK) 



 Login    Register 






















Home


Report Categories







Premium Reports

Access to 600000+ Premium Reports











  
                                Aerospace & Defense
                              









  
                                Agri & Food
                              









  
                                Automotive
                              









  
                                Basic Materials
                              











  
                                Consumer Goods & Retail
                              









  
                                Energy
                              









  
                                Life Sciences
                              









  
                                Manufacturing & Construction
                              











  
                                Services
                              









  
                                Telecom & IT
                              









  
                                Education
                              









  
                                Security & Intelligence Systems
                              











  
                                Technology
                              









  
                                Company Reports
                              










Report Categories 










Aerospace & Defense
                





Agri & Food
                





Automotive
                





Basic Materials
                







Consumer Goods & Retail
                





Energy
                





Life Sciences
                





Manufacturing & Construction
                







Services
                





Telecom & IT
                





Education
                





Security & Intelligence Systems
                







Technology
                





Company Reports
                








Publisher
Knowledgestore

Countries 
              


Browse by Country
Browse by Continent
Browse by Group / Region



 Conferences
              


Upcoming Conferences
Seminars




 Conferences
              


Upcoming Conferences
Seminars




Countries 

Browse by Country
Browse by Continent
Browse by Group / Region



News & Blog

 Press Release
Blog



News & Blogs

 Press Release
Blogs


FAQs

About Us

About Our Company
Our Team
Life At WGR


Careers
Contact Us











                                         There are no items currently in your basket.
                                     













There are no items currently in your basket!














  




































Search 
                






 














Home
All Reports
GTx, Inc. - Product Pipeline Review - 2016









 


  GTx, Inc. - Product Pipeline Review - 2016


WGR515108
25 
                  May, 2016 
Global
47 pages 
Global Markets Direct






















Description




Table of Content




Sample Report




Enquiry before buy




Related Reports





GTx, Inc. - Product Pipeline Review - 2016
Summary
Global Markets Direct’s, ‘GTx, Inc. - Product Pipeline Review - 2016’, provides an overview of the GTx, Inc.’s pharmaceutical research and development focus. 
The report provides comprehensive information on the therapeutics under development by GTx, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the pipeline therapeutic landscape of GTx, Inc.
- The report provides overview of GTx, Inc. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report assesses GTx, Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report features GTx, Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
Reasons to buy
- Evaluate GTx, Inc.’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for GTx, Inc.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding GTx, Inc.’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
GTx, Inc. Snapshot 5
GTx, Inc. Overview 5
Key Information 5
Key Facts 5
GTx, Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
GTx, Inc. - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
GTx, Inc. - Pipeline Products Glance 11
GTx, Inc. - Clinical Stage Pipeline Products 11
Phase II Products/Combination Treatment Modalities 11
GTx, Inc. - Early Stage Pipeline Products 12
Preclinical Products/Combination Treatment Modalities 12
GTx, Inc. - Drug Profiles 13
enobosarm 13
Product Description 13
Mechanism of Action 13
R&D Progress 13
GTx-758 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
Beta-LGND2 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
GTx-026 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
Gtx-027 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
Gtx-186 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
Gtx-230 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
GTx-878 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
Small Molecules to Antagonize Androgen Receptor for Metastatic Castration Resistant Prostate Cancer 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Small Molecules to Inhibit AKR1C3 for Prostate Cancer and Castration Resistant Prostate Cancer 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Small Molecules to Inhibit Tubulin for Cancer 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
GTx, Inc. - Pipeline Analysis 27
GTx, Inc. - Pipeline Products by Target 27
GTx, Inc. - Pipeline Products by Route of Administration 28
GTx, Inc. - Pipeline Products by Molecule Type 29
GTx, Inc. - Pipeline Products by Mechanism of Action 30
GTx, Inc. - Recent Pipeline Updates 31
GTx, Inc. - Dormant Projects 40
GTx, Inc. - Discontinued Pipeline Products 41
Discontinued Pipeline Product Profiles 41
toremifene citrate 41
GTx, Inc. - Company Statement 42
GTx, Inc. - Locations And Subsidiaries 45
Head Office 45
Appendix 46
Methodology 46
Coverage 46
Secondary Research 46
Primary Research 46
Expert Panel Validation 46
Contact Us 46
Disclaimer 47
List of Tables
GTx, Inc., Key Information 5
GTx, Inc., Key Facts 5
GTx, Inc. - Pipeline by Indication, 2016 8
GTx, Inc. - Pipeline by Stage of Development, 2016 9
GTx, Inc. - Monotherapy Products in Pipeline, 2016 10
GTx, Inc. - Phase II, 2016 11
GTx, Inc. - Preclinical, 2016 12
GTx, Inc. - Pipeline by Target, 2016 27
GTx, Inc. - Pipeline by Route of Administration, 2016 28
GTx, Inc. - Pipeline by Molecule Type, 2016 29
GTx, Inc. - Pipeline Products by Mechanism of Action, 2016 30
GTx, Inc. - Recent Pipeline Updates, 2016 31
GTx, Inc. - Dormant Developmental Projects,2016 40
GTx, Inc. - Discontinued Pipeline Products, 2016 41
List of Figures
GTx, Inc. - Pipeline by Top 10 Indication, 2016 7
GTx, Inc. - Pipeline by Stage of Development, 2016 9
GTx, Inc. - Monotherapy Products in Pipeline, 2016 10
GTx, Inc. - Pipeline by Target, 2016 27
GTx, Inc. - Pipeline by Route of Administration, 2016 28
GTx, Inc. - Pipeline by Molecule Type, 2016 29
GTx, Inc. - Pipeline Products by Mechanism of Action, 2016 30







                                Request a Sample Report
                                




Name:*










Email:*


(Optional: Request you to please fill in your Corporate Email-ID)



Job Title:*





Company:*





Phone No:*





Your Country:*

--select country--
Afghanistan
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antigua & Barbuda
Argentina
Armenia
Aruba
Australia
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia
Bosnia & Herzegovina
Botswana
Brazil
Brunei
Bulgaria
Burkina Faso
Burundi
Cambodja
Cameroon
Canada
Cape Verde
Cayman Islands
Central African Republic
Chad
Chile
China
Colombia
Comoros
Congo-Brazzaville
Congo-Kinshasa
Cook Islands
Costa Rica
Cote d"Ivoire
Croatia
Cuba
Cyprus
Czech Republic
Denmark
Djibouti
Dominica
Dominican Republic
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Falkland (Malvinas)
Faroes
Fiji
Finland
France
French-Guiana
Tahiti(French Polinesia)
Gabon
Gambia
Georgia
Germany
Ghana
Gibraltar
Greece
Greenland
Grenada
Guadeloupe
Guam
Guatemala
Guinea
Guinea-Bissau
Guyana
Haiti
Vatican City
Honduras
Hong Kong
Hungary
Iceland
India
Indonesia
Iran
Iraq
Ireland
Israel
Italy
Jamaica
Japan
Jordan
Kazakhstan
Kenya
Kiribati
North Korea
South Korea
Kuwait
Kyrgyzstan
Laos
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macao
Macedonia
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique
Mauritania
Mauritius
Mexico
Micronesia
Moldova
Monaco
Mongolia
Montserrat
Morocco
Mozambique
Myanmar
Namibia
Nauru
Nepal
Netherlands
Netherlands Antilles
New Caledonia
New Zealand
Nicaragua
Niger
Nigeria
Norfolk
Northern Mariana
Norway
Oman
Pakistan
Palau
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn
Poland
Portugal
Puerto Rico
Qatar
Reunion
Romania
Russian Federation
Rwanda
Saint Helena
Saint Lucia
Saint Pierre and Miquelon
St Vincent & the Grenadines
Samoa
San Marino
Sao Tome & Principe
Saudi Arabia
Senegal
Seychelles
Sierra Leone
Singapore
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
Spain
Sri Lanka
Sudan
Suriname
Svalbard and Jan Mayen
Swaziland
Sweden
Switzerland
Syria
Taiwan
Tajikistan
Tanzania
Thailand
Togo
Tokelau
Tonga
Trinidad & Tobago
Tunisia
Turkey
Turkmenistan
Turks and Caicos Islands
Tuvalu
Uganda
Ukraine
United Arab Emirates
United Kingdom
United States of America
Uruguay
Uzbekistan
Vanuatu
Venezuela
Viet Nam
Virgin Islands British
Virgin Islands US
Wales
Western Sahara
Yemen
Zambia
Zimbabwe
Timor-Leste
Curacao
St Kitts & Nevis
Sint Maarten
Guernsey
Isle of Man
Jersey
Niue
Montenegro



Do you have any Specific field of Interest?*

















Confirm


 








Make an enquiry before buying this Report




Name:*










Email:*


(Optional: Request you to please fill in your Corporate Email-ID)



Job Title:*





Company:*





Phone No:*





Your Country:*

--select country--
Afghanistan
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antigua & Barbuda
Argentina
Armenia
Aruba
Australia
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia
Bosnia & Herzegovina
Botswana
Brazil
Brunei
Bulgaria
Burkina Faso
Burundi
Cambodja
Cameroon
Canada
Cape Verde
Cayman Islands
Central African Republic
Chad
Chile
China
Colombia
Comoros
Congo-Brazzaville
Congo-Kinshasa
Cook Islands
Costa Rica
Cote d"Ivoire
Croatia
Cuba
Cyprus
Czech Republic
Denmark
Djibouti
Dominica
Dominican Republic
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Falkland (Malvinas)
Faroes
Fiji
Finland
France
French-Guiana
Tahiti(French Polinesia)
Gabon
Gambia
Georgia
Germany
Ghana
Gibraltar
Greece
Greenland
Grenada
Guadeloupe
Guam
Guatemala
Guinea
Guinea-Bissau
Guyana
Haiti
Vatican City
Honduras
Hong Kong
Hungary
Iceland
India
Indonesia
Iran
Iraq
Ireland
Israel
Italy
Jamaica
Japan
Jordan
Kazakhstan
Kenya
Kiribati
North Korea
South Korea
Kuwait
Kyrgyzstan
Laos
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macao
Macedonia
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique
Mauritania
Mauritius
Mexico
Micronesia
Moldova
Monaco
Mongolia
Montserrat
Morocco
Mozambique
Myanmar
Namibia
Nauru
Nepal
Netherlands
Netherlands Antilles
New Caledonia
New Zealand
Nicaragua
Niger
Nigeria
Norfolk
Northern Mariana
Norway
Oman
Pakistan
Palau
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn
Poland
Portugal
Puerto Rico
Qatar
Reunion
Romania
Russian Federation
Rwanda
Saint Helena
Saint Lucia
Saint Pierre and Miquelon
St Vincent & the Grenadines
Samoa
San Marino
Sao Tome & Principe
Saudi Arabia
Senegal
Seychelles
Sierra Leone
Singapore
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
Spain
Sri Lanka
Sudan
Suriname
Svalbard and Jan Mayen
Swaziland
Sweden
Switzerland
Syria
Taiwan
Tajikistan
Tanzania
Thailand
Togo
Tokelau
Tonga
Trinidad & Tobago
Tunisia
Turkey
Turkmenistan
Turks and Caicos Islands
Tuvalu
Uganda
Ukraine
United Arab Emirates
United Kingdom
United States of America
Uruguay
Uzbekistan
Vanuatu
Venezuela
Viet Nam
Virgin Islands British
Virgin Islands US
Wales
Western Sahara
Yemen
Zambia
Zimbabwe
Timor-Leste
Curacao
St Kitts & Nevis
Sint Maarten
Guernsey
Isle of Man
Jersey
Niue
Montenegro



Your Enquiry*

















Confirm


 
















Purchase this Market Research Report







 USD




 GBP




 EURO




 YEN




 INR







                        1-user PDF
                         
                          $1,500.00
                        

 
                        Site PDF 
                         
                          $3,000.00
                        

 
                        Enterprise PDF 
                         
                          $4,500.00
                        





  1-user PDF
  
 
    1,152.60
   

 
  Site PDF 
  
 
  2,305.20
  

 
  Enterprise PDF 
  
 
  3,457.80
  





  1-user PDF
  
 
    1,284.90
   

 
  Site PDF 
  
 
  2,569.80
  

 
  Enterprise PDF 
  
 
  3,854.70
  





  1-user PDF
  
 
    166,474.50
   

 
  Site PDF 
  
 
  332,949.00
  

 
  Enterprise PDF 
  
 
  499,423.50
  





  1-user PDF
  
 
    96,637.50
   

 
  Site PDF 
  
 
  193,275.00
  

 
  Enterprise PDF 
  
 
  289,912.50
  









Add To Cart
BUY NOW





 















  Email Report


  Sample Report




  Save Page


  Any Questions




  Download information


  Check Discount




  Download Order Form









  Email Report


  Sample Report




  Save Page


  Any Questions




  Download information


  Check Discount




  Download Order Form






Contact Us










Akash Anand
Domain Head Business Development
sales@wiseguyreports.com
+1 (646) 843 9312 (US)
+44 208 133 9349 (UK)













Rishabh Arora
Domain Head Business Development
sales@wiseguyreports.com
+44-208-133-9346













Abu Koshy
Domain Head Business Development
sales@wiseguyreports.com
+1 339 368 6938










Related Reports








                  ×
              
Tell a friend about this report 




Your Name:*





Your Email:*





Friend's Name:*





Friend's Email:*





Your Enquiry*









Send


 







































































GTx, Inc. - Product Pipeline Review - 2016 | Market Research Reports® Inc.



















Skip to main content









 








Home
FAQs
Contact Us
Become Publisher
Blog
 





0 items $0.00 











Search form

Search this site 
 

Search



 










You are here: Home  Catalog  Pharma & Healthcare  Company Reports (Pharma & Healthcare) 









GTx, Inc. - Product Pipeline Review - 2016











GTx, Inc. - Product Pipeline Review - 2016









Printer versionSend by email





Publication ID: GMD0516092
Publication Date: 

May 25, 2016



Pages: 

47


Publisher: Global Markets Direct
Countries: 

Global


$1,500.00
Publication Type *
 - Select -Single User License (PDF), $1,500.00Site License (PDF), $3,000.00Global License (PDF), $4,500.00
Please choose the suitable license type from above. More details are at given under tab "Report License Types" below.




Add to cart





Why to buy from us?




 Globally Trusted Brand


We help executives from Fortune 500 firms to Start-ups with their market research needs thus we can help you too. 





 Shop With Confidence


If you have any pre-sales questions related to this report pelase let us know using the "Report Enquiry" form below. This will help us provide you with answers so that you can purchase with confidence. 





 Secure Checkout


You can shop confidently as your online payments are processed using PCI DSS compliant secure payment gateways on our website.





 Frequently Asked Questions


If you wish to read about frequently asked questions by our customers please visit our FAQs page.










TabsDescription

GTx, Inc. - Product Pipeline Review - 2016
Summary
Global Markets Direct’s, ‘GTx, Inc. - Product Pipeline Review - 2016’, provides an overview of the GTx, Inc.’s pharmaceutical research and development focus. 
The report provides comprehensive information on the therapeutics under development by GTx, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the pipeline therapeutic landscape of GTx, Inc.
- The report provides overview of GTx, Inc. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses GTx, Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features GTx, Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
Reasons to buy
- Evaluate GTx, Inc.’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for GTx, Inc.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding GTx, Inc.’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope




Table of Contents

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
GTx, Inc. Snapshot 5
GTx, Inc. Overview 5
Key Information 5
Key Facts 5
GTx, Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
GTx, Inc. - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
GTx, Inc. - Pipeline Products Glance 11
GTx, Inc. - Clinical Stage Pipeline Products 11
Phase II Products/Combination Treatment Modalities 11
GTx, Inc. - Early Stage Pipeline Products 12
Preclinical Products/Combination Treatment Modalities 12
GTx, Inc. - Drug Profiles 13
enobosarm 13
Product Description 13
Mechanism of Action 13
R&D Progress 13
GTx-758 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
Beta-LGND2 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
GTx-026 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
Gtx-027 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
Gtx-186 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
Gtx-230 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
GTx-878 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
Small Molecules to Antagonize Androgen Receptor for Metastatic Castration Resistant Prostate Cancer 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Small Molecules to Inhibit AKR1C3 for Prostate Cancer and Castration Resistant Prostate Cancer 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Small Molecules to Inhibit Tubulin for Cancer 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
GTx, Inc. - Pipeline Analysis 27
GTx, Inc. - Pipeline Products by Target 27
GTx, Inc. - Pipeline Products by Route of Administration 28
GTx, Inc. - Pipeline Products by Molecule Type 29
GTx, Inc. - Pipeline Products by Mechanism of Action 30
GTx, Inc. - Recent Pipeline Updates 31
GTx, Inc. - Dormant Projects 40
GTx, Inc. - Discontinued Pipeline Products 41
Discontinued Pipeline Product Profiles 41
toremifene citrate 41
GTx, Inc. - Company Statement 42
GTx, Inc. - Locations And Subsidiaries 45
Head Office 45
Appendix 46
Methodology 46
Coverage 46
Secondary Research 46
Primary Research 46
Expert Panel Validation 46
Contact Us 46
Disclaimer 47
List of Tables
GTx, Inc., Key Information 5
GTx, Inc., Key Facts 5
GTx, Inc. - Pipeline by Indication, 2016 8
GTx, Inc. - Pipeline by Stage of Development, 2016 9
GTx, Inc. - Monotherapy Products in Pipeline, 2016 10
GTx, Inc. - Phase II, 2016 11
GTx, Inc. - Preclinical, 2016 12
GTx, Inc. - Pipeline by Target, 2016 27
GTx, Inc. - Pipeline by Route of Administration, 2016 28
GTx, Inc. - Pipeline by Molecule Type, 2016 29
GTx, Inc. - Pipeline Products by Mechanism of Action, 2016 30
GTx, Inc. - Recent Pipeline Updates, 2016 31
GTx, Inc. - Dormant Developmental Projects,2016 40
GTx, Inc. - Discontinued Pipeline Products, 2016 41
List of Figures
GTx, Inc. - Pipeline by Top 10 Indication, 2016 7
GTx, Inc. - Pipeline by Stage of Development, 2016 9
GTx, Inc. - Monotherapy Products in Pipeline, 2016 10
GTx, Inc. - Pipeline by Target, 2016 27
GTx, Inc. - Pipeline by Route of Administration, 2016 28
GTx, Inc. - Pipeline by Molecule Type, 2016 29
GTx, Inc. - Pipeline Products by Mechanism of Action, 2016 30




Companies Covered


NA




Report License Types

Single User License (PDF)
This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Global License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.
 
Site License (PDF)*
This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Global License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.
 
Global License (PDF)*
This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
*If Applicable.




Report Enquiry


Do you have more questions related to this market research report after going through the description and table of contents?
We are here to help. Please use the form given below to let us know your questions related to this report.
Kindly use your official email address and contact number to ensure speedy response.


First Name *



Last Name *



Company *



Email Address *



Phone (Including International Code) *



Report Title *



Your Inquiry *








CAPTCHAThis question is for testing whether you are a human visitor and to prevent automated spam submissions.


Math question *
 7 + 0 =  
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.


Submit




Company Reports (Pharma & Healthcare)Pharma & Healthcare

*Please note that the report cover image shown above is for representation purpose only. Actual report cover may vary.








 1500.00000
Single User License (PDF)

Market Research Reports® Inc.
http://www.marketresearchreports.com












Related Market Research Reports







Publication 

Price 





Siemens Healthcare GmbH - Medical Equipment - Deals and Alliances Profile
Summary 

$250.00 



Invacare Corporation (IVC) - Medical Equipment - Deals and Alliances Profile
Summary 

$250.00 



OPKO Health Inc (OPK) - Medical Equipment - Deals and Alliances Profile
Summary 

$250.00 



ReVision Optics Inc - Medical Equipment - Deals and Alliances Profile
Summary 

$250.00 



Bioptix Inc (BIOP) - Medical Equipment - Deals and Alliances Profile
Summary 

$250.00 



Biolase, Inc. (BIOL) - Medical Equipment - Deals and Alliances Profile
Summary 

$250.00 



CorMatrix Cardiovascular Inc - Medical Equipment - Deals and Alliances Profile
Summary 

$250.00 



BioTime Inc (BTX) - Medical Equipment - Deals and Alliances Profile
Summary 

$250.00 



Medtronic Plc (MDT) - Medical Equipment - Deals and Alliances Profile
Summary 

$250.00 



TransMedics Inc - Medical Equipment - Deals and Alliances Profile
Summary 

$250.00 



Veracyte Inc (VCYT) - Medical Equipment - Deals and Alliances Profile
Summary 

$250.00 



iRhythm Technologies Inc (IRTC) - Medical Equipment - Deals and Alliances Profile
Summary 

$250.00 




 









Clients Who Trust Us

 











Need tailor made market research solution? We can help you with that too.

Contact Us










About Us

At Market Research Reports, Inc. we aim to make it easier for decision makers to find relevant information and locate right market research reports which can save their time and assist in what they do best, i.e. take time-critical decisions.
We work with our associate Global market research firms who are known leaders in their respective domains to obtain right market research solution for our customer’s needs, be it custom research or syndicated research reports.





Contact Us


Market Research Reports, Inc

















16192 Coastal Hwy
Lewes, DE 19958, USA
 USA: +1-302-703-9904
 India: +91-8762746600
 marketresearchreports
[email protected]
 




User login


Username *
 


Password *
 

Create new account
Request new password


Log in
 




Latest Blog Posts



  
 Investment Opportunities in Taiwan: Semiconductor, Chemical and Consumer Goods will Lead the Pack 

 Global Investment Opportunities in Ports and Terminals 
 
 


Stay Connected







 



Sign up to our newsletter:
Email Address *
 



Subscribe
 





 




Research Industries

Home
Automotive
Banking & Finance
Business & Government
Chemicals
Computing & Electronics
Consumer & Retail
Energy & Utilities
Food & Beverages
Industry & Manufacturing
Marketing & Advertising
Media
Pharma & Healthcare
Telecom
Transport
Travel & Leisure
 









Our Company

About Us
Publications By Country
FAQs
Privacy Policy
Terms & Conditions
 







© Copyright 2010-17 Market Research Reports, Inc.. All Rights Reserved. M Market Research Reports and the M Market Research Reports Logo are registered trademarks of Market Research Reports, Inc.
Disclaimer: Market Research Reports, Inc. has no affiliation to, and is not associated with any other website(s) or organization(s). We offer syndicated research reports (like country analysis, SWOT analysis, competitive intelligence, industry reports, company reports and market analysis & trends reports) and custom market research from our website MarketResearchReports.com only.
If you are looking for a market research solution for your research requirements, please begin your search using the search box on top of this page or use our chat system to speak to our market research consultants or directly write to us.
 











GTx, Inc. - Product Pipeline Review - 2015, Trends, Share, Size Research Report

























866-997-4948(US-Canada Toll Free)

















Home




Global Markets Direct




Pharmaceutical




GTx, Inc. - Product Pipeline Review - 2015









GTx, Inc. - Product Pipeline Review - 2015
Published By : Global Markets Direct
Published Date :  Jul 2015
Category : Pharmaceutical
No. of Pages : 46 Pages

 



Description
Table of Content

Check Discount


                    GTx, Inc. - Product Pipeline Review - 2015SummaryGlobal Markets Directs, GTx, Inc. - Product Pipeline Review - 2015, provides an overview of the GTx, Inc.s pharmaceutical research and development focus.This report provides comprehensive information on the current therapeutic developmental pipeline of GTx, Inc.s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.Scope- The report provides brief overview of GTx, Inc. including business description, key information and facts, and its locations and subsidiaries- The report reviews current pipeline of GTx, Inc.s human therapeutic division and enlists all their major and minor projects- The report features product description and descriptive mechanism of action for key pipeline products along with the products developmental history and major milestones - Special feature on out-licensed and partnered product portfolio- The report summarizes all the dormant and discontinued pipeline projects- Latest company statement - Latest news and deals relating to the GTx, Inc.s pipeline productsReasons to buy- Evaluate GTx, Inc.s strategic position with total access to detailed information on its product pipeline- Assess the growth potential of GTx, Inc. in its therapy areas of focus- Identify new drug targets and therapeutic classes in the GTx, Inc.s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps- Develop strategic initiatives by understanding the focus areas of GTx, Inc. and exploit collaboration and partnership opportunities- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage- Plan mergers and acquisitions effectively by identifying the most promising pipeline of GTx, Inc.- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope- Explore the dormant and discontinued projects of GTx, Inc. and identify potential opportunities in those areas- Avoid Intellectual Property Rights related issues                

                                            Table of ContentsTable of Contents 2List of Tables 4List of Figures 4GTx, Inc. Snapshot 5GTx, Inc. Overview 5Key Information 5Key Facts 5GTx, Inc. - Research and Development Overview 6Key Therapeutic Areas 6GTx, Inc. - Pipeline Review 9Pipeline Products by Stage of Development 9Pipeline Products - Monotherapy 10GTx, Inc. - Pipeline Products Glance 11GTx, Inc. - Late Stage Pipeline Products 11Phase III Products/Combination Treatment Modalities 11GTx, Inc. - Clinical Stage Pipeline Products 12Phase II Products/Combination Treatment Modalities 12GTx, Inc. - Early Stage Pipeline Products 13Preclinical Products/Combination Treatment Modalities 13Discovery Products/Combination Treatment Modalities 14GTx, Inc. - Drug Profiles 15enobosarm 15Product Description 15Mechanism of Action 15R&D Progress 15GTx-758 17Product Description 17Mechanism of Action 17R&D Progress 17Beta-LGND2 19Product Description 19Mechanism of Action 19R&D Progress 19Gtx-186 21Product Description 21Mechanism of Action 21R&D Progress 21Gtx-230 22Product Description 22Mechanism of Action 22R&D Progress 22Small Molecule to Inhibit Tubulin for Cancer 23Product Description 23Mechanism of Action 23R&D Progress 23Small Molecules to Inhibit AKR1C3 for Prostate Cancer and Castration Resistant Prostate Cancer 24Product Description 24Mechanism of Action 24R&D Progress 24Small Molecules to Antagonize Androgen Receptor for Metastatic Castration Resistant Prostate Cancer 25Product Description 25Mechanism of Action 25R&D Progress 25GTx, Inc. - Pipeline Analysis 26GTx, Inc. - Pipeline Products by Target 26GTx, Inc. - Pipeline Products by Route of Administration 27GTx, Inc. - Pipeline Products by Molecule Type 28GTx, Inc. - Pipeline Products by Mechanism of Action 29GTx, Inc. - Recent Pipeline Updates 30GTx, Inc. - Dormant Projects 38GTx, Inc. - Discontinued Pipeline Products 39Discontinued Pipeline Product Profiles 39toremifene citrate 39GTx, Inc. - Company Statement 40GTx, Inc. - Locations And Subsidiaries 44Head Office 44Appendix 45Methodology 45Coverage 45Secondary Research 45Primary Research 45Expert Panel Validation 45Contact Us 45Disclaimer 46List of TablesGTx, Inc., Key Information 5GTx, Inc., Key Facts 5GTx, Inc. - Pipeline by Indication, 2015 8GTx, Inc. - Pipeline by Stage of Development, 2015 9GTx, Inc. - Monotherapy Products in Pipeline, 2015 10GTx, Inc. - Phase III, 2015 11GTx, Inc. - Phase II, 2015 12GTx, Inc. - Preclinical, 2015 13GTx, Inc. - Discovery, 2015 14GTx, Inc. - Pipeline by Target, 2015 26GTx, Inc. - Pipeline by Route of Administration, 2015 27GTx, Inc. - Pipeline by Molecule Type, 2015 28GTx, Inc. - Pipeline Products by Mechanism of Action, 2015 29GTx, Inc. - Recent Pipeline Updates, 2015 30GTx, Inc. - Dormant Developmental Projects,2015 38GTx, Inc. - Discontinued Pipeline Products, 2015 39List of FiguresGTx, Inc. - Pipeline by Top 10 Indication, 2015 7GTx, Inc. - Pipeline by Stage of Development, 2015 9GTx, Inc. - Monotherapy Products in Pipeline, 2015 10GTx, Inc. - Pipeline by Top 10 Target, 2015 26GTx, Inc. - Pipeline by Top 10 Route of Administration, 2015 27GTx, Inc. - Pipeline by Top 10 Molecule Type, 2015 28GTx, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015 29                                         
                                    







Make an enquiry before buying this Report
Please fill the enquiry form below.



Full Name *


Your Email *


Job Title *

Company *

Phone No. *
                                    (Pls. Affix Country Code)



Message

Security Code *

60267












 



Choose License Type : 

Select User License
Single License User $1500
Multiple License User $3000







Do you wish to check sample of this report? Order a sample report.



Have query on this report?



Related News

Zinc Prices to Continue to Shoot as Hopes of Output Rise Remain Bleak


Shift to Cloud-based Products and Services Fares well for Microsoft


India Remains Leading Provider of Online Labors in Technology and Software Development Sector 


Flipkart’s PhonePe Ventures in India’s Offline Space


India Introduces First Train Powered by Solar Power 





Research Assistance
We will be happy to help you find what you need. Please call us or write to us:
866-997-4948
(US-Canada Toll Free)
Tel : +1-518-621-2074
	Email : sales@researchmoz.us
 





